Medizinische Klinik D

Besucher*innen unabhängig vom Immunisierungsstatus sowie andere externe Personen
Alle Besucher*innen (ab dem Grundschulalter) sowie Dienstleister*innen, Handwerker*innen und andere dienstliche Besucher*innen müssen unabhängig von ihrem Immunisierungsstatus beim Einlass einen negativen dokumentierten Antigen-Schnelltest (nicht älter als 24 Stunden) oder einen negativen PCR-Test (nicht älter als 48 Stunden) vorweisen. Das heißt, auch geimpfte und/oder genesene Personen müssen zwingend ein negatives Testergebnis vorlegen können.

Bitte beachten Sie: Medizinisch notwendige Begleitpersonen wie Eltern, Erziehungsberechtigte oder Betreuer gelten nach einem Erlass des Landes NRW nicht als Besucher*innen. Für sie gelten je nach Fall die Vorgaben für ambulante beziehungsweise stationäre Patient*innen.

Ambulante Patient*innen (3G-Regelung)
Für ambulante Patient*innen gilt die 3G-Regelung: Sie müssen entweder vollständig geimpft oder genesen sein oder einen dokumentierten negativen Antigen-Schnelltest (nicht älter als 24 Stunden) oder einen PCR-Test (nicht älter als 48 Stunden) vorweisen. Der Nachweis von 3G gilt auch für Kinder und Jugendliche ab dem Grundschulalter. Ein Schülerausweis als Nachweis ist im Krankenhaus nicht ausreichend. Bei symptomfreien Kindern unter 6 Jahren muss kein Test vorgelegt werden.

Diese 3G-Regelung gilt auch für medizinisch notwendige Begleitpersonen. Begleitpersonen sind nur zulässig, wenn dies aus medizinischen oder persönlichen Gründen zwingend erforderlich ist (z.B. bei Kindern, bei Geburten, Personen mit Behinderungen).

Stationäre Patient*innen
Patienten, die geplant stationär aufgenommen oder ambulant operiert werden, müssen einen negativen PCR-Test (nicht älter als 48 Stunden) nachweisen. Andere stationäre Patient*innen werden weiterhin kurz vor dem stationären Aufenthalt durch das UKM in der UKM-Corona-Teststelle getestet. Diese Regelung gilt auch für medizinisch notwendige Begleitpersonen, die zusammen mit Patient*innen stationär aufgenommen werden.

Stationäre aufgenommene Begleitpersonen mit 2G dürfen die Cafeteria besuchen und vor Ort essen. Für nicht geimpfte und/oder genesene stationär aufgenommene Begleitpersonen gilt: Jeweils eine Begleitperson pro Patient (keine Kinder oder weitere Personen zusätzlich) hat mit einem tagesaktuellen und offiziellen Antigen-Schnelltesttest (nicht älter als 24 Std.) Zutritt zur Cafeteria und darf die gewählte Verpflegung ausschließlich „to go“ mitnehmen. Ein Verzehr vor Ort ist nicht gestattet.

Notfälle
Notfälle werden weiterhin auch ohne den Nachweis einer Immunisierung oder Testnachweis behandelt, hier erfolgen notwendige Test in den Notaufnahmen.

Bitte beachten Sie: Um unsere Patienten, Mitarbeitenden und Besucher vor einer Infektion zu schützen und die Ausbereitung von SARS-CoV2 einzudämmen, ist in allen Gebäuden des UKM das Tragen einer medizinischen Maske (OP-Maske oder FFP2-Maske) erforderlich. Stoffmasken können nicht verwendet werden. Achtung: Auch FFP-Masken mit Ausatemventil sind nicht erlaubt.

Für den Besuch des UKM dürfen Sie Ihre eigenen, privaten Masken nutzen. Sollten Sie keine Maske dabei haben, stellen wir Ihnen für Dauer ihres Aufenthaltes im Klinikum an der jeweiligen Pforte einen geeigneten Schutz zur Verfügung.

Das Betreten der Gebäude ist ohne medizinische Maske nicht gestattet.

Informationen für stationäre Patient*innen

Patient*innen, die geplant stationär aufgenommen oder ambulant operiert werden, müssen einen negativen PCR-Test (nicht älter als 48 Stunden) nachweisen. Andere stationäre Patient*innen werden weiterhin kurz vor dem stationären Aufenthalt durch das UKM in der UKM-Corona-Teststelle getestet. Diese Regelung gilt auch für medizinisch notwendige Begleitpersonen, die zusammen mit Patient*innen stationär aufgenommen werden.

Stationäre aufgenommene Begleitpersonen mit 2G dürfen die Cafeteria besuchen und vor Ort essen. Für nicht geimpfte und/oder genesene stationär aufgenommene Begleitpersonen gilt: Jeweils eine Begleitperson pro Patient (keine Kinder oder weitere Personen zusätzlich) hat mit einem tagesaktuellen und offiziellen Antigen-Schnelltesttest (nicht älter als 24 Std.) Zutritt zur Cafeteria und darf die gewählte Verpflegung ausschließlich „to go“ mitnehmen. Ein Verzehr vor Ort ist nicht gestattet.

Informationen für ambulante Patient*innen | Ambulanzen und Sprechstunden

Für ambulante Patient*innen gilt die 3G-Regelung: Sie müssen entweder vollständig geimpft oder genesen sein oder einen dokumentierten negativen Antigen-Schnelltest (nicht älter als 24 Stunden) oder einen PCR-Test (nicht älter als 48 Stunden) vorweisen. Der Nachweis von 3G gilt auch für Kinder und Jugendliche ab dem Grundschulalter. Ein Schülerausweis als Nachweis ist im Krankenhaus nicht ausreichend. Bei symptomfreien Kindern unter 6 Jahren muss kein Test vorgelegt werden.

Diese 3G-Regelung gilt auch für medizinisch notwendige Begleitpersonen. Begleitpersonen sind nur zulässig, wenn dies aus medizinischen oder persönlichen Gründen zwingend erforderlich ist (z.B. bei Kindern, bei Geburten, Personen mit Behinderungen).

Der Schutz unserer Patientinnen und Patienten, unserer Mitarbeitenden und auch Ihr Schutz stehen für uns an erster Stelle.

Jeder Patient*in darf pro Tag für eine Stunde einen Besucher*in empfangen. Dies gilt ab dem ersten Aufenthaltstag. Besonders gefährdete Bereiche können abweichende Regelungen erlassen. Die einstündigen Besuche sind möglich in der Zeit von 8 bis 19 Uhr. Die Zutrittsberechtigung wird vor Ort erteilt. Bitte beachten Sie: Der Besuch durch eine weitere Person am selben Tag ist leider nicht möglich.

Alle Besucher*innen (ab dem Grundschulalter) müssen unabhängig von ihrem Immunisierungsstatus beim Einlass einen negativen dokumentierten Antigen-Schnelltest (nicht älter als 24 Stunden) oder einen negativen PCR-Test (nicht älter als 48 Stunden) vorweisen. Das heißt, auch geimpfte und/oder genesene Personen müssen zwingend ein negatives Testergebnis vorlegen können. Besuchende dürfen grundsätzlich keine Symptome einer möglichen COVID-19-Erkrankung haben.

Bitte beachten Sie: Medizinisch notwendige Begleitpersonen wie Eltern, Erziehungsberechtigte oder Betreuer gelten nach einem Erlass des Landes NRW nicht als Besucher*innen. Für sie gelten je nach Fall die Vorgaben für ambulante beziehungsweise stationäre Patient*innen.

Die öffentliche Teststelle der Münsterschen Haus- und Fachärzte (Medis Münster) am UKM hat den Betrieb zum 30.06.2021 eingestellt. Derzeit werden auf dem Gelände keine öffentlichen Testungen mehr durchgeführt. Personen mit Corona-verdächtigen Symptomen, fraglichem Kontakt zu Corona-Infizierten oder roter App-Warnung sowie Reiserückkehrer oder Lehrer:innen/Erzieher:innen wenden sich an den Hausarzt oder erfragen unter T 116117 die jeweils zuständige Teststelle und deren Öffnungszeiten. Alternativ hat die Stadt Münster eine Liste mit allen Teststellen in Münster zusammengestellt.

Die Teststelle des UKM, an der ausschließlich Patient:innen sowie stationär aufgenommene Begleitpersonen getestet werden, bleibt geöffnet.

Publikationen Med D

(Kursiv: Mitarbeiter/Inn Med. Klinik D; * geteilte Erst- oder/und Letztautorschaften)

A. Erst- oder/und Letztautorschaften

  1. Buscher K, Heitplatz B, Van Marck V, Song J, Loismann S, Rixen R, Hüchtmann B, Kurian S, Ehinger E, Wolf D, Ley K, Pavenstaedt H, Reuter S. Data Driven Kidney Transplant Phenotyping as a Histology-independent Framework for Biomarker Discovery. J Am Soc Nephrol. 2021 Jun 2:ASN.2020121685. doi: 10.1681/ASN.2020121685. Epub ahead of print. PMID: 34078665. IF2020: 10,121
  2. Ciarimboli G. Regulation Mechanisms of Expression and Function of Organic Cation Transporter 1. Front Pharmacol. 2021 Jan 21;11:607613. doi: 10.3389/fphar.2020.607613. PMID: 33732143; PMCID: PMC7959823. . IF2020: 5,81
  3. Ciarimboli G. Physiology, Biochemistry, and Pharmacology of Transporters forOrganic Cations. Int J Mol Sci. 2021 Jan 13;22(2):732. doi: 10.3390/ijms22020732. PMID: 33450934; PMCID: PMC7828435. IF2020: 5,923
  4. Engelbertz C, Pinnschmidt HO, Freisinger E, Reinecke H, Schmitz B, Fobker M, Schmieder RE, Wegscheider K, Breithardt G, Pavenstädt H, Brand E. Sex-specific differences and long-term outcome of patients with coronary artery disease and chronic kidney disease: the Coronary Artery Disease and Renal Failure (CAD-REF) Registry. Clin Res Cardiol. 2021 May 26. doi: 10.1007/s00392-021-01864-5. Epub ahead of print. PMID: 34036426. IF2020: 5,46
  5. Finke M, Pin M, Bernhard M, Rovas A, Pavenstädt HJ, Kümpers P. Isolationsmaßnahmen, Diagnostik und Organisation in deutschen Notaufnahmen während der COVID-19-Pandemie 2020 [Isolation precautions, diagnostics and organization in German emergency departments during the 2020 COVID-19 pandemic]. Med Klin Intensivmed Notfmed. 2021 Jan 24:1–8. German. doi: 10.1007/s00063-021-00775-7. Epub ahead of print. PMID: 33491106; PMCID:PMC7829031. IF2020: 0,840
  6. Heiden S, Siwek R, Lotz ML, Borkowsky S, Schröter R, Nedvetsky P, Rohlmann A,Missler M, Krahn MP. Apical-basal polarity regulators are essential for slitdiaphragm assembly and endocytosis in Drosophila nephrocytes. Cell Mol Life Sci.2021 Apr;78(7):3657- 3672. doi: 10.1007/s00018-02103769-y. Epub 2021 Mar 2.PMID: 33651172; PMCID: PMC8038974. IF2020: 9,261
  7. Hermann A, Wu G, Nedvetsky PI, Brücher VC, Egbring C, Bonse J, Höffken V,Wennmann DO, Marks M, Krahn MP, Schöler H, Heiduschka P, Pavenstädt H, Kremerskothen J. The Hippo pathway component Wwc2 is a key regulator ofembryonic development and angiogenesis in mice. Cell Death Dis. 2021 Jan22;12(1):117. doi: 10.1038/s41419-021-03409-0. PMID: 33483469; PMCID:PMC7822818. IF2020: 8,469
  8. Höffken V, Hermann A, Pavenstädt H, Kremerskothen J. WWC Proteins: Important Regulators of Hippo Signaling in Cancer. Cancers (Basel). 2021 Jan 15;13(2):306.doi: 10.3390/cancers13020306. PMID: 33467643; PMCID: PMC7829927. IF2020: 6,639
  9. Jehn U, Schütte-Nütgen K, Bautz J, Pavenstädt H, Suwelack B, Thölking G,Reuter S. Clinical features of BK-polyomavirus and cytomegalovirus co-infection after kidney transplantation. Sci Rep. 2020 Dec 29;10(1):22406. doi: 10.1038/s41598-020-79799-6. PMID: 33376243; PMCID: PMC7772341. IF2020: 4,379
  10. Jehn U, Schütte-Nütgen K, Henke U, Pavenstädt H, Suwelack B, Reuter S. Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients. Sci Rep. 2021 Feb 12;11(1):3713. doi: 10.1038/s41598-021- 83333-7. PMID: 33580120; PMCID:PMC7880993. IF2020: 4,379
  11. Lenders M, Scharnetzki D, Heidari A, Di Iorio D, Wegner SV, Brand E. Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease. Int J Mol Sci. 2021 Mar 6;22(5):2680. doi: 10.3390/ijms22052680. PMID: 33800950; PMCID: PMC7961705. IF2020: 5,923
  12. Lenders M, Nordbeck P, Kurschat C, Eveslage M, Karabul N, Kaufeld J, Hennermann JB, Patten M, Cybulla M, Müntze J, Üçeyler N, Liu D, Das AM, Sommer C, Pogoda C, Reiermann S, Duning T, Gaedeke J, von Cossel K, Blaschke D, Brand SM, Alexander Mann W, Kampmann C, Muschol N, Canaan-Kühl S, Brand E. Treatment of fabry disease with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). Eur Heart J Cardiovasc Pharmacother. 2021 Mar 16:pvab025. doi: 10.1093/ehjcvp/pvab025. Epub ahead of print. PMID:33725118. IF2020: 6,617
  13. Lenders M, Brand E. Fabry Disease: The Current Treatment Landscape. Drugs.2021 Apr;81(6):635-645. doi: 10.1007/s40265-021-01486-1. Epub 2021 Mar 15. PMID: 33721270; PMCID: PMC8102455. IF2020: 9,546
  14. Lepa C, Hoppe S, Stöber A, Skryabin BV, Sievers LK, Heitplatz B, Ciarimboli G, Neugebauer U, Lindenmeyer MT, Cohen CD, Drexler HCA, Boor P, Weide T, Pavenstädt H, George B. TrkC Is Essential for Nephron Function and Trans-Activates Igf1R Signaling. J Am Soc Nephrol. 2021 Feb;32(2):357-374. doi:10.1681/ASN.2020040424. Epub 2020 Dec 30. PMID: 33380522; PMCID: PMC8054883. IF2020: 10,121
  15. Lüttgenau SM, Emming C, Wagner T, Harms J, Guske J, Weber K, Neugebauer U, Schröter R, Panichkina O, Pethő Z, Weber F, Schwab A, Wege AK, Nedvetsky P, Krahn MP. Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6. Mol Cancer. 2021 May 4;20(1):74. doi: 10.1186/s12943-021-01354-2. PMID: 33941200; PMCID: PMC8094600. IF2020: 27,401
  16. Möller-Kerutt A, Rodriguez-Gatica JE, Wacker K, Bhatia R, Siebrasse JP, Boon N, Van Marck V, Boor P, Kubitscheck U, Wijnholds J, Pavenstädt H, Weide T. Crumbs2 Is an Essential Slit Diaphragm Protein of the Renal Filtration Barrier. J Am Soc Nephrol. 2021 May 3;32(5):1053-1070. doi: 10.1681/ASN.2020040501. Epub 2021 Mar 9. PMID: 33687977. IF2020: 10,121
  17. Rovas A, Sackarnd J, Rossaint J, Kampmeier S, Pavenstädt H, Vink H, Kümpers P. Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study. Crit Care. 2021 Mar 19;25(1):112. doi: 10.1186/s13054-021-03520-w. PMID: 33741036; PMCID:PMC7980588. IF2020: 9,097
  18. Rovas A, Osiaevi I, Buscher K, Sackarnd J, Tepasse PR, Fobker M, Kühn J, Braune S, Göbel U, Thölking G, Gröschel A, Pavenstädt H, Vink H, Kümpers P. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis. 2021 Feb;24(1):145-157. doi: 10.1007/s10456-020-09753-7. Epub 2020 Oct 14. PMID: 33058027; PMCID: PMC7556767. IF2020: 9,596
  19. Schorn S, Dicke AK, Neugebauer U, Schröter R, Friedrich M, Reuter S, Ciarimboli G. Expression and Function of Organic Cation Transporter 2 in Pancreas. Front Cell Dev Biol. 2021 May 28;9:688885. doi:10.3389/fcell.2021.688885. PMID: 34124075; PMCID: PMC8195675. IF2020: 6,684
  20. Thölking G, Reuter S. Commentary: The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients. Front Pharmacol. 2021 Feb 23;12:603345. doi:10.3389/fphar.2021.603345. PMID: 33692688; PMCID: PMC7938239. IF2020: 5,81
  21. Wiening V, Schmidt T, Dahmen M, Siam S, Reuter S, Pavenstädt HJ, Sester M, Suwelack B. Case Report: Management of a Multidrug-Resistant CMV-Strain in a Renal Transplant Recipient by High-Dose CMV-Specific Immunoglobulins, Modulation in Immunosuppression, and Induction of CMV-Specific Cellular Immunity. Front Immunol. 2021 Jan 25;11:623178. doi: 10.3389/fimmu.2020.623178. PMID: 33569064; PMCID: PMC7868410. IF2020: 7,561

B. Koautorschaften

  1. Becker F, Mehdorn AS, Getsopulos V, Schütte-Nütgen K,Reuter S, Suwelack B, Pascher A, Brockmann JG, Bahde R. Tumor Recurrence and Graft Survival in Renal Transplant Recipients with a History of Pretransplant Malignancy: A Matched Pair Analysis. J Clin Med. 2021 May 27;10(11):2349. doi: 10.3390/jcm10112349. PMID: 34071904; PMCID: PMC8199231. IF2020: 4,241
  2. Beckmann D, Römer-Hillmann A, Krause A, Hansen U, Wehmeyer C, Intemann J, de Gorter DJJ, Dankbar B, Hillen J, Heitzmann M, Begemann I, Galic M, Weinhage T, Foell D, Ai R, Kremerskothen J, Kiener HP, Müller S, Kamradt T, Schröder C, Leitão E, Horsthemke B, Rosenstiel P, Nordström K, Gasparoni G, Gasparoni N, Walter J, Li N, Yang X, Chung HR, Pavenstädt H, Lindemann N, Schnittler HJ, Wang W, Firestein GS, Pap T, Korb-Pap A. Lasp1 regulates adherens junction dynamics and fibroblast transformation in destructive arthritis. Nat Commun. 2021 Jun 15;12(1):3624. doi: 10.1038/s41467-021-23706-8. PMID: 34131132. IF2020: 14,919
  3. Brücher VC, Egbring C, Plagemann T, Nedvetsky PI, Höffken V, Pavenstädt H, Eter N, Kremerskothen J, Heiduschka P. Lack of WWC2 Protein Leads to Aberrant Angiogenesis in Postnatal Mice. Int J Mol Sci. 2021 May 18;22(10):5321. doi:10.3390/ijms22105321. PMID: 34070186; PMCID: PMC8158494. IF2020: 5,923
  4. Hauser IA, Marx S, Sommerer C, Suwelack B, Dragun D, Witzke O, Lehner F, Schiedel C, Porstner M, Thaiss F, Neudörfl C, Falk CS, Nashan B, Sester M. Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results. Eur J Immunol. 2021 Apr;51(4):943-955. doi: 10.1002/eji.202048855. Epub 2020 Dec 28. PMID: 33306229. IF2020: 5,532
  5. Hernández-Lozano I, Mairinger S, Sauberer M, Stanek J, Filip T, Wanek T, Ciarimboli G, Tournier N, Langer O. Influence of Cation Transporters (OCTs and MATEs) on the Renal and Hepatobiliary Disposition of [11C]Metoclopramide in Mice. Pharm Res. 2021 Jan;38(1):127-140. doi:10.1007/s11095-021-03002-2. Epub 2021 Feb 8. PMID: 33559045; PMCID: PMC7902338. IF2020: 4,20
  6. Hobohm L, Kölmel S, Niemann C, Kümpers P, Krieg VJ, Bochenek ML, Lukasz AH, Reiss Y, Plate KH, Liebetrau C, Wiedenroth CB, Guth S, Münzel T, Hasenfuß G, Wenzel P, Mayer E, Konstantinides SV, Schäfer K, Lankeit M. Role of angiopoietin-2 in venous thrombus resolution and chronic thromboembolic disease. Eur Respir J. 2021 May 13:2004196. doi: 10.1183/13993003.04196-2020. Epub aheadof print. PMID: 33986029. IF2020: 16,671
  7. Imeri F, Stepanovska Tanturovska B, Schwalm S, Saha S, Zeng-Brouwers J, Pavenstädt H, Pfeilschifter J, Schaefer L, Huwiler A. Loss of sphingosine kinase 2 enhances Wilm's tumor suppressor gene 1 and nephrin expression in podocytes and protects from streptozotocin-induced podocytopathy and albuminuria in mice. Matrix Biol. 2021 May 17:S0945-053X(21)00043-3. doi:10.1016/j.matbio.2021.05.003. Epub ahead of print. PMID: 34015468. IF2020: 11,583
  8. Money ME, Hamroun A, Shu Y, Matthews C, Ahmed Eltayeb S, Ciarimboli G, Metz CN. Case Report and Supporting Documentation: Acute Kidney Injury Manifested as Oliguria Is Reduced by Intravenous Magnesium Before Cisplatin. Front Oncol. 2021 Feb 26;11:607574. doi: 10.3389/fonc.2021.607574. PMID: 33718160; PMCID:PMC7952862. IF2020: 6,244
  9. Marki A, Buscher K, Lorenzini C, Meyer M, Saigusa R, Fan Z, Yeh YT, Hartmann N, Dan JM, Kiosses WB, Golden GJ, Ganesan R, Winkels H, Orecchioni M, McArdle S, Mikulski Z, Altman Y, Bui J, Kronenberg M, Chien S, Esko JD, Nizet V, Smalley D, Roth J, Ley K. Elongated neutrophil-derived structures are blood-borne microparticles formed by rolling neutrophils during sepsis. J Exp Med. 2021 Mar 1;218(3):e20200551. doi: 10.1084/jem.20200551. PMID: 33275138; PMCID: PMC7721910. IF2020: 14,307
  10. Michael M, Kumle B, Pin M, Kümpers P, Gröning I, Bernhard M. Nichttraumatologisches Schockraummanagement [Nontraumatic resuscitation room management of critically ill patients]. Med Klin Intensivmed Notfmed. 2021 Jun;116(5):405- 414. German. doi: 10.1007/s00063-021-00789-1. Epub 2021 Feb 18.PMID: 33599782; PMCID: PMC7891119. IF2020: 0,840
  11. Möckel M, Stegemann MS, Burst V, Kümpers P, Risse J, Koehler FC, Schunk D, Hitzek J, Dietrich TE, Slagman A. Which parameters support disposition decision in suspected COVID-19 cases in the emergency department (ED): a German clinicalcohort study. BMJ Open. 2021 Mar 31;11(3):e044853. doi:10.1136/bmjopen-2020-044853. PMID: 33789854; PMCID: PMC8015792 IF2020: 2,692.
  12. Swaroop B SS, Kanumuri R, Ezhil I, Naidu Sampangi JK, Kremerskothen J, Rayala SK, Venkatraman G. KIBRA connects Hippo signaling and cancer. Exp Cell Res. 2021 Jun 15;403(2):112613. doi: 10.1016/j.yexcr.2021.112613. Epub 2021 Apr 24. PMID: 33901448. IF2020: 3,905

A. Erst- und/oder Letztautorschaften                        Stand 04.01.2021

  1. Amrhein J, Drynda S, Schlatt L, Karst U, Lohmann CH, Ciarimboli G, Bertrand J. Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA. Int J Mol Sci. 2020;21(18):6632. doi: 10.3390/ijms21186632.
  2. Bartmann I, Schütte-Nütgen K, Suwelack B, Reuter S. Early postoperative calculation of the tacrolimus concentration-to-dose ratio does not predict outcomes after kidney transplantation. Transpl Int. 2020;33(6):689-691. doi: 10.1111/tri.13605.
  3. Bayraktar S*, Nehrig J*, Menis E, Karli K, Janning A, Struk T, Halbritter J, Michgehl U, Krahn MP, Schuberth CE*, Pavenstädt H*, Wedlich-Söldner R*.  A Deregulated Stress Response Underlies Distinct INF2-Associated Disease Profiles. J Am Soc Nephrol. 2020;31(6):1296-1313. doi: 10.1681/ASN.2019111174.*equally contribution
  4. Buscher K, Reuter S. Neue Ansätze zur Detektion von Abstoßungen und Transplantatschädigungen. Nieren- und Hochdruckerkrankungen 2020; 49(9):390-394
  5. Costa ACC, Yamamoto PA, Lauretti GR, de Lima Benzi JR, Zanelli CF, Barz V, Ciarimboli G, de Moraes NV. Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. J Clin Pharmacol. 2020. doi: 10.1002/jcph.1603
  6. Flothow DJG, Suwelack B, Pavenstädt H, Schütte-Nütgen K, Reuter S. The Effect of Proton Pump Inhibitor Use on Renal Function in Kidney Transplanted Patients. J Clin Med. 2020;9(1):258. doi: 10.3390/jcm9010258.
  7. Hesse B, Rovas A, Buscher K, Kusche-Vihrog K, Brand M, Di Marco GS, Kielstein JT, Pavenstädt H, Linke WA, Nofer JR, Kümpers P, Lukasz A. Symmetric dimethylarginine in dysfunctional high-density lipoprotein mediates endothelial glycocalyx breakdown in chronic kidney disease. Kidney Int. 2020;97(3):502-515. doi: 10.1016/j.kint.2019.10.017.
  8. Hessler, M., Nelis, P., Ertmer, C., Alnawaiseh, M., Lehmann, F., Schmidt, C., ... & Rovas, A*. (2020). Optical coherence tomography angiography as a novel approach to contactless evaluation of sublingual microcirculation: A proof of principle study. Scientific reports, 10(1), 1-10.  doi: 10.1038/s41598-020-62128-2
  9. Jehn U, Schütte-Nütgen K, Henke U, Bautz J, Pavenstädt H, Suwelack B, Reuter S. Prognostic Value of Growth Differentiation Factor 15 in Kidney Donors and Recipients. J Clin Med. 2020;9(5):1333. doi: 10.3390/jcm9051333.
  10. Jehn U, Schütte-Nütgen K, Bautz J, Pavenstädt H, Suwelack B, Thölking G, Heinzow H, Reuter S. Cytomegalovirus Viremia after Living and Deceased Donation in Kidney Transplantation. J Clin Med. 2020;9(1):252. doi: 10.3390/jcm9010252.
  11. Jehn U, Schütte-Nütgen K, Bautz J, Pavenstädt H, Suwelack B, Thölking G, Reuter S. Clinical features of BK-polyomavirus and cytomegalovirus co-infection after kidney transplantation. Sci Rep. 2020 Dec 29;10(1):22406. doi: 10.1038/s41598-020-79799-6.
  12. Jehn U, Görlich D, Reuter S. The Estimation Formula for the Urinary Albumin-Creatinine Ratio Based on the Protein-Creatinine Ratio Are Not Valid for a Kidney Transplant and a Living Donor Cohort. J Am Soc Nephrol. 2020;31(8):1915-1916. doi: 10.1681/ASN.2020050545.
  13. Kantauskaitė M, Hucke A, Reike M, Ahmed Eltayeb S, Xiao C, Barz V, Ciarimboli G. Rapid regulation of human multidrug and extrusion transporters hMATE1 and hMATE2K. Int J Mol Sci 2020;21(14):E5157. doi: 10.3390/ijms21145157.
  14. Lenders M, Nordbeck P, Kurschat C, Karabul N, Kaufeld J, Hennermann JB, Patten M, Cybulla M, Müntze J, Üçeyler N, Liu D, Das AM, Sommer C, Pogoda C, Reiermann S, Duning T, Gaedeke J, Stumpfe K, Blaschke D, Brand SM, Mann WA, Kampmann C, Muschol N, Canaan-Kühl S, Brand E. Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS). Clin Pharmacol Ther. 2020. doi: 10.1002/cpt.1832.
  15. Lenders M, Brand E. FAbry STabilization indEX (FASTEX): Clinical evaluation of disease progression in Fabry patients. Mol Genet Metab. 2020;129(2):142-149.doi: 10.1016/j.ymgme.2019.12.010.
  16. Lenders M, Boutin M, Auray-Blais C, Brand E. Effects of orally delivered alpha-galactosidase A on gastrointestinal symptoms in patients with Fabry disease. Gastroenterology. 2020: S0016-5085(20)34759-4. doi: 10.1053/j.gastro.2020.06.007.
  17. Lenders M, Nordbeck P, Canaan-Kühl S, Kreul L, Duning T, Lorenz L, Pogoda C, Brand SM, Wanner C, Brand E. J Med Genet. 2020:jmedgenet-2020-106874. doi: 10.1136/jmedgenet-2020-106874.
  18. Lepa C, Möller-Kerutt A, Stölting M, Picciotto C, Eddy ML, Butt E, Kerjaschki D, Korb-Pap A, Vollenbröker B, Weide T, George B, Kremerskothen J, Pavenstädt H. LIM and SH3 protein 1 (LASP-1): A novel link between the slit membrane and actin cytoskeleton dynamics in podocytes. FASEB J. 2020;34(4):5453-5464. doi: 10.1096/fj.201901443R. Epub 2020 Feb 21.
  19. Lepa C, Hoppe S, Stöber A, Skryabin BV, Sievers LK, Heitplatz B, Ciarimboli G, Neugebauer U, Lindenmeyer MT, Cohen CD, Drexler HCA, Boor P, Weide T, Pavenstädt H, George B. TrkC Is Essential for Nephron Function and Trans-Activates Igf1R Signaling. JASN December 2020, ASN.2020040424
  20. Möller-Kerutt A, Rodriguez-Gatica JE, Wacker K, Bhatia R, Siebrasse JP, Boon N, Van Marck V, Boor P, Kubitschek U, Wijnhold J, Pavenstädt H, Weide T. Crumbs2 is an essential slit diaphragm protein of the renal filtration barrier. JASN, accepted
  21. Mueller N, Streis J, Müller S, Pavenstädt H, Felderhoff T, Reuter S, Busch V. Pulse Wave Analysis and Pulse Wave Velocity for Fistula Assessment.Kidney Blood Press Res. 2020:1-13. doi: 10.1159/000506741. Online ahead of print.
  22. Reuter S, Suwelack B. Editorial.Nieren- und Hochdruckerkrankungen 2020; 49(9):379-380
  23. Rovas A*.Osiaevi I*, Buscher K, Sackarnd J, Tepasse PR, Fobker M, Kühn J, Braune S, Göbel U, Thölking G, Gröschel A, Pavenstädt H, Vink H, Kümpers P. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis. 2020:1-13. doi: 10.1007/s10456-020-09753-7
  24. Scharnetzki D, Stappers F, Lenders M, Brand E. Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant α-galactosidase A in patients with Fabry disease. Mol Genet Metab. 2020 Aug 28:S1096-7192(20)30187-6
  25. Stappers F, Scharnetzki D, Schmitz B, Manikowski D, Brand SM, Grobe K, Lenders M*, Brand E*. Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity. J Inherit Metab Dis. 2020;43(2):334-347.doi: 10.1002/jimd.12176.
  26. Struk T, Nair V, Eichinger F, Kretzler M, Wedlich-Söldner R, Bayraktar S, Pavenstädt H. Transcriptome analysis of primary podocytes reveals novel calcium regulated regulatory networks. FASEB J. 2020;34(11):14490-14506. doi: 10.1096/fj.201902493RR.
  27. Suwelack B, Bunnapradist S, Meier-Kriesche U, Stevens DR, Procaccianti C, Morganti R, Budde K. Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial. Ann Transplant 2020;25:e923278. doi: 10.12659/AOT.923278.
  28. Thölking G, Gillhaus NH, Schütte-Nütgen K, Pavenstädt H, Koch R, Suwelack B, Reuter S. Conversion to Everolimus was Beneficial and Safe for Fast and Slow Tacrolimus Metabolizers After Renal Transplantation. J Clin Med. 2020;9(2):328. doi: 10.3390/jcm9020328.
  29. Wennmann DO, Dlugos CP, Hofschröer A, Hennies M, Kühn J, Hafezi W, Kampmeier S, Mellmann A, Triphaus S, Sackarnd J, Tepasse P, Keller M, Van Aken H, Pavenstädt H, Kümpers P. Handling of COVID-19 in the emergency department: Field report of the emergency ward of the University Hospital Münster. Med Klin Intensivmed Notfmed. 2020;115(5):380-387.
  30. Wenning C, Vrachimis A, Pavenstädt HJ, Reuter S*, Schäfers M. Coronary artery calcium burden, carotid atherosclerotic plaque burden, and myocardial blood flow in patients with end-stage renal disease: A non-invasive imaging study combining PET/CT and 3D ultrasound. J Nucl Cardiol. 2020. doi: 10.1007/s12350-020-02080-w. Online ahead of print.

 B. Koautorschaften

  1. Blazquez R, Rietkötter E, Wenske B, Wlochowitz D, Sparrer D, Vollmer E, Müller G, Seegerer J, Sun X, Dettmer K, Barrantes-Freer A, Stange L, Utpatel K, Bleckmann A, Treiber H, Bohnenberger H, Lenz C, Schulz M, Reimelt C, Hackl C, Grade M, Büyüktas D, Siam L, Balkenhol M, Stadelmann C, Kube D, Krahn MP, Proescholdt MA, Riemenschneider MJ, Evert M, Oefner PJ, Klein CA, Hanisch UK, Binder C, Pukrop T. LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer. Int J Cancer. 2020; 146: 3170–3183. doi: 10.1002/ijc.32742.
  2. Brons JK, Vink SN, de Vos MGJ, Reuter S, Dobrindt U, van Elsas JD. Fast identification of Escherichia coli in urinary tract infections using a virulence gene based PCR approach in a novel thermal cycler. J Microbiol Methods. 2020; 169:105799. doi:10.1016/j.mimet.2019.105799
  3. Correa-Martínez CL, Kampmeier S, Kümpers P, Schwierzeck V, Hennies M, Hafezi W, Kühn J, Pavenstädt H, Ludwig S, Mellmann A. A Pandemic in Times of Global Tourism: Superspreading and Exportation of COVID-19 Cases From a Ski Area in Austria. J Clin Microbiol. 2020;58(6):e00588-20.
  4. Ettinger M, Savov P, Calliess T, Windhagen H, Lichtinghagen R, Lukasz A, Omar M. Improved diagnostic accuracy with the classification tree method for diagnosing low-grade periprosthetic joint infections by quantitative measurement of synovial fluid alpha-defensin and C-reactive protein. Int Orthop. 2020;44(1):31-38. doi: 10.1007/s00264-019-04338-6.
  5. Guttmann S, Nadzemova O, Grünewald I, Lenders M, Brand E, Zibert A, Schmidt HH. ATP7B knockout disturbs copper and lipid metabolism in Caco-2 cells. PLoS One. 2020;15(3):e0230025. doi: 10.1371/journal.pone.0230025.
  6. Hadem J, Rossnick R, Hesse B, Herr M, Hansen M, Bergmann A, Kensah G, Maess C, Baraki H, Kümpers P, Lukasz A, Kutschka I. Endothelial dysfunction following coronary artery bypass grafting: Influence of patient and procedural factors. Herz. 2020;45(1):86-94. doi: 10.1007/s00059-018-4708-0
  7. Hartmann C, Schwietzer YA, Kummer D, Kirschnick N, Hoppe E, Thüring EM, Glaesner-Ebnet M, Brinkmann F, Gerke V, Reuter S, Nakayama M, Ebnet K. The mitochondrial outer membrane protein SYNJ2BP interacts with the cell adhesion molecule TMIGD1 and can recruit it to mitochondria. BMC Mol Cell Biol. 2020;21(1):30. doi: 10.1186/s12860-020-00274-1.
  8. Katou S, Vogel T, Morgul H, Eichelmann AK, Becker F, Slepecka P, Boehmer K, Reichelt D, Reuter S, Pascher A, Suwelack B, Brockmann J. ABO-Incompatible Living Donor Kidney Transplantation in a Human Immunodeficiency Virus-Positive Recipient From a Human Immunodeficiency Virus-Positive Donor: A Case Report. Transplant Proc. 2020;52(9):2739-2741. doi: 10.1016/j.transproceed.2020.07.008
  9. Meersch M, Küllmar M, Pavenstädt H, Rossaint J, Kellum JA, Martens S, Klausmeyer P, Schmidt EA, Kerschke L, Zarbock A. Effects of Different Doses of Remote Ischemic Preconditioning on Kidney Damage Among Patients Undergoing Cardiac Surgery: A Single-Center Mechanistic Randomized Controlled Trial. Crit Care Med. 2020. doi: 10.1097/CCM.0000000000004415.
  10. Mehdorn AS, Reuter S, Suwelack B, Schütte-Nütgen K, Becker F, Senninger N, Palmes D, Vogel T, Bahde R. Comparison of kidney allograft survival in the Eurotransplant senior program after changing the allocation criteria in 2010-A single center experience. PLoS One. 2020;15(7):e0235680. doi: 10.1371/journal.pone.0235680.
  11. Myers KR, Yu K, Kremerskothen J, Butt E, Zheng JQ. The Nebulin Family LIM and SH3 Proteins Regulate Postsynaptic Development and Function. J Neurosci. 2020, 40 (3) 526-541. pii: 0334-19. doi: 10.1523/JNEUROSCI.0334-19.2019.
  12. Pfeuffer S, Rolfes L, Bormann E, Sauerland C, Ruck T, Schilling M, Melzer N, Brand M, Pul R, Kleinschnitz C, Wiendl H, Meuth SG. Comparing plasma exchange to escalated methyl prednisolone in refractory multiple sclerosis relapses. J Clin Med. 2020, 9(1), 35. pii: E35. doi: 10.3390/jcm9010035
  13. Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Budde K, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J; STOP-IgAN Investigators. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98(4):1044-1052. doi: 10.1016/j.kint.2020.04.046.
  14. Rolfes L, Pfeuffer S, Ruck T, Windhagen S, Oschlies I, Pavenstädt H, Angenendt L, Wiendl H, Krämer J, Meuth SG. A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 2019;7(1):e638. doi: 10.1212/NXI.0000000000000638. Print 2020 Jan.  
  15. Schlatt L, Costa ACC, Barz V, Ciarimboli G, Karst U. Fast Simultaneous Quantification of Gabapentin and Cetirizine in Cell Lysates by Means of HPLC-MS/MS. J Pharm Biomed Anal. 2020;184:113172. doi: 10.1016/j.jpba.2020.113172.
  16. Skryabin BV, Kummerfeld DM, Gubar L, Seeger B, Kaiser H, Stegemann A, Roth J, Meuth SG, Pavenstädt H, Sherwood J, Pap T, Wedlich-Söldner R, Sunderkötter C, Schwartz YB, Brosius J, Rozhdestvensky TS. Pervasive head-to-tail insertions of DNA templates mask desired CRISPR/Cas9-mediated genome editing events. Science Advances 2020;6(7):eaax2941. doi: 10.1126/sciadv.aax2941.
  17. van der Veen SJ, Vlietstra WJ, van Dussen L, van Kuilenburg ABP, Dijkgraaf MGW, Lenders M, Brand E, Wanner C, Hughes D, Elliott PM, Hollak CEM, Langeveld M. Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease. Int J Mol Sci. 2020;21(16):5784. doi: 10.3390/ijms21165784.
  18. Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP. Blood Adv. 2020;4(13):3093-3101. doi: 10.1182/bloodadvances.2020001987.
  19. Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020;4(13):3085-3092. doi: 10.1182/bloodadvances.2020001973.

C. Reviews 

  1. Blazquez R, Sparrer D, Wendl C, Evert M, Riemenschneider MJ, Krahn MP, Erez N, Proescholdt M, Pukrop T. The macro-metastasis/organ parenchyma interface (MMPI) - A hitherto unnoticed area. Semin Cancer Biol. 2020;60:324-333. doi: 10.1016/j.semcancer.2019.10.012.
  2. Ciarimboli G, Theil G, Bialek J, Edemir B. Contribution and Expression of Organic Cation Transporters and Aquaporin Water Channels in Renal Cancer. Rev Physiol Biochem Pharmacol. 2020. doi: 10.1007/112_2020_34.
  3. Ciarimboli G. Fishing for protective compounds. Elife. 2020;9:e61547. doi: 10.7554/eLife.61547
  4. Deharde D, Klockenbusch W, Schmitz R, Brand M, Köster HA, de KO Hydroxychloroquine as a Preventive and Therapeutic Option in Preeclampsia - a Literature Review. Geburtshilfe Frauenheilkd. 2020;80(7):679-685. doi: 10.1055/a-1170-5145.
  5. Krahn MP. Phospholipids of the Plasma Membrane - Regulators or Consequence of Cell Polarity? Front Cell Dev Biol. 2020;8:277. doi: 10.3389/fcell.2020.00277. 
  6. Lenders M, Stappers F, Brand E. In Vitro and In Vivo Amenability to Migalastat in Fabry Disease.Mol Ther Methods Clin Dev. 2020 Aug 20;19:24-34. 
  7. Messerer DAC, Halbgebauer R, Nilsson B, Pavenstädt H, Radermacher P, Huber-Lang M. Immunopathophysiology of trauma-related acute kidney injury. Nat Rev Nephrol. 2020 Sep 21. 
  8. Schütte-Nütgen K, Thölking G, Suwelack B, Reuter S. Tacrolimus - Pharmacokinetic Considerations for Clinicians. Curr Drug Metab. 2018;19(4):342-350. 
  9. Strauss M, Leischik R, Jehn U, Padberg JS, Pistulli R, Kümpers P, Reinecke H. The hypertensive emergency situation: Recommendations for initial drug therapy management. Med Klin Intensivmed Notfmed. 2020. doi: 10.1007/s00063-020-00728-6
  10. Wiening V, Schmidt T, Dahmen M, Siam S, Reuter S, Pavenstädt H, Sester M, Suwelack B. Management of a multidrug-resistant CMV-strain in a renal transplant recipient by high-dose CMV-specific immunoglobulins, modulation in immunosuppression and induction of CMV-specific cellular immunity – a case report. Frontiers in Immunology

A. Erst- oder/und Letztautorschaften

  1. Abo Basha J, Kiel M, Görlich D, Schütte-Nütgen K, Witten A, Pavenstädt H, Kahl BC, Dobrindt U*, Reuter S*. Phenotypic and Genotypic Characterization of Escherichia coli Causing Urinary Tract Infections in Kidney-Transplanted Patients. J Clin Med. 2019;8(7). pii: E988.
  2. Angenendt L, Huss S, Schliemann C, Reuter S. Pure red cell aplasia after kidney transplantation Am J Transplant. 2019;19(6):1864-1866. doi: 10.1111/ajt.15356.
  3. Dahmen M, Becker F, Pavenstädt H, Suwelack B, Schütte-Nütgen K*, Reuter S*. Validation of the Kidney Donor Profile Index (KDPI) to assess a deceased donor's kidneys' outcome in a European cohort. Sci Rep. 2019;9(1):11234.
  4. Dlugos CP, Picciotto C, Krakow M, Stöber A, Weide T, Jeibmann A, Krahn M, Van Marck V, Klingauf J, Nüsse H, Wedlich-Söldner R, Pavenstädt P, Klämbt C, and George B. Nephrin signaling results in C3G-dependent Integrin β1 activation. J Am Soc Nephrol. 2019;30(6):1006-1019. doi: 10.1681/ASN.2018040362.
  5. Drost CC, Rovas A, Kusche-Vihrog K, Van Slyke P, Kim H, Hoang VC, Maynes JT, Wennmann DO, Pavenstädt H, Linke W, Lukasz A, Hesse B, Kümpers P. Thromb Haemost. 2019;119(11):1827-1838. doi: 10.1055/s-0039-1695768.
  6. Frenzel D, Köppen C, Bauer OB, Karst U, Schröter R, Tzvetkov MV, Ciarimboli G. Effects of Single Nucleotide Polymorphism Ala270Ser (rs316019) on the Function and Regulation of hOCT2. Biomolecules. 2019; 7;9(10).
  7. Hadem J, Kielstein JT, Manns MP, Kümpers P, Lukasz A. Outcomes of renal dysfunction in patients with acute liver failure. United European Gastroenterol J. 2019;7(3):388-396. doi: 10.1177/2050640618817061.
  8. Harrach S, Barz V, Pap T, Pavenstädt H, Schlatter E, Edemir B, Distler J, Ciarimboli G*, Bertrand J*: Notch-signaling activity determines uptake and biological effect of imatinib in systemic sclerosis dermal fibroblasts. J Invest Dermatol. 2019; 139 (2), 439-447. pii: S0022-202X(18)32642-3. doi: 10.1016/j.jid.2018.08.021.
  9. Hucke A, Rinschen MM, Bauer OB, Sperling M, Karst U, Köppen C, Sommer K, Schröter R, Ceresa C, Chiorazzi A, Canta A, Semperboni S, Marmiroli P, Cavaletti G, Schlatt S, Schlatter E, Pavenstädt H, Heitplatz B, Van Marck V, Sparreboom A, Barz V, Knief A, Deuster D, Zehnhoff-Dinnesen AA, Ciarimboli G. An integrative approach to cisplatin chronic toxicities in mice reveals importance of organic cation-transporter-dependent protein networks for renoprotection. Arch Toxicol. 2019;93(10):2835-2848. doi: 10.1007/s00204-019-02557-9.
  10. Jehn U, Schuette-Nuetgen K, Bautz J, Suwelack B, Reuter S. Valganciclovir is not a risk factor of BK polyomavirus (BKPyV) viremia. Am J Transplant. 2019; 19(12):3436-3437 doi: 10.1111/ajt.15610.
  11. Jehn U, Schuette-Nuetgen K, Kentrup D, Hoerr V, Reuter S . Renal Allograft Rejection: Noninvasive Ultrasound- and MRI-Based Diagnostics. Contrast Media Mol Imaging. 2019:3568067. doi: 10.1155/2019/3568067
  12. Köhnke R, Heitplatz B, Reuter S. Mulberry-shaped gingiva after kidney transplantation. Am J Transplant. 2019;19(12):3429–3431
  13. Köhnke R, Kentrup D, Schütte-Nütgen K, Schäfers M, Schnöckel U, Hoerr V, Reuter S. Update on imaging-based diagnosis of acute renal allograft rejection. Am J Nucl Med Mol Imaging. 2019;9(2):110-126
  14. Lenders M*, Stappers F*, Niemietz C, Schmitz B, Boutin M, Ballmaier PJ, Zibert A, Schmidt H, Brand SM, Auray-Blais C, Brand E. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. J Med Genet. 2019;56(8):548-556.
  15. Mewes M, Lenders M, Stappers F, Scharnetzki D, Nedele J, Fels J, Wedlich-Söldner R, Brand SM, Schmitz B*, Brand E*. Soluble adenylyl cyclase (sAC) regulates calcium signaling in the vascular endothelium. FASEB J. 2019;33(12):13762-13774.
  16. Oswald S, Müller J, Neugebauer U, Schröter R, Herrmann E, Pavenstädt H and Ciarimboli G. Protein Abundance of Clinically Relevant Drug Transporters in The Human Kidneys. Int J Mol Sci 2019, 20, 5303; doi:10.3390/ijms20215303
  17. Rovas A, Seidel LM, Vink H, Pohlkötter T, Pavenstädt H, Ertmer C, Hessler M, Kümpers P. Association of sublingual microcirculation parameters and endothelial glycocalyx dimensions in resuscitated sepsis. Crit Care. 2019;23(1):260. doi: 10.1186/s13054-019-2542-2.
  18. Schütte-Nütgen K*, Finke M*, Ehlert S, Thölking G, Pavenstädt H, Suwelack B, Palmes D, Bahde R, Koch R*, Reuter S*. Expanding the donor pool in kidney transplantation: Should organs with acute kidney injury be accepted?-A retrospective study. PLoS One. 2019;14(3):e0213608. doi: 10.1371/journal.pone.0213608.
  19. Schütte-Nütgen K*, Thölking G*, Steinke J, Pavenstädt H, Schmidt R, Suwelack B, Reuter S. Fast Tac Metabolizers at Risk ⁻ It is Time for a C/D Ratio Calculation. J Clin Med. 2019;8(5).
  20. Schütte-Nütgen K: Getting a Notch closer to renal dysfunction: activated Notch suppresses expression of the adaptor protein Disabled-2 in tubular epithelial cells. FASEB J. 2019;33(1):821-832. doi: 10.1096/fj.201800392RR
  21. Snieder B, Brast S, Grabner A, Buchholz S, Schröter R, Spoden GA, Florin L, Salomon J, Albrecht T, Barz V, Sparreboom A, Ciarimboli G. Identification of the Tetraspanin CD9 as an Interaction Partner of Organic Cation Transporters 1 and 2. SLAS Discov. 2019;24(9):904-914. doi: 10.1177/2472555219859837
  22. Thölking G*, Schütte-Nütgen K*, Schmitz J, Rovas A, Dahmen M, Bautz J, Jehn U, Pavenstädt H, Heitplatz B, Van Marck V, Suwelack B, Reuter S. A Low Tacrolimus Concentration/Dose Ratio Increases the Risk for the Development of Acute Calcineurin Inhibitor-Induced Nephrotoxicity. J Clin Med. 2019;8(10). pii: E1586.
  23. Thölking G, Reuter S. Alternative Viewpoint on Tacrolimus Concentration-to-Dose Ratios in Kidney Transplant Recipients and Relationship to Clinical Outcomes. Pharmacotherapy. 2019;39(10):1036-1037. doi: 10.1002/phar.2321.
  24. Wewers TM, Mayer AB, Pfleiderer A, Beul K, Schmidt R, Heitplatz B, Van Marck V, Nolte I, Pavenstädt H, Reuter S, Brand M, Di Marco GS. Increased soluble fms-like tyrosine kinase 1 after ischemia reperfusion contributes to adverse clinical outcomes following kidney transplantation. Kidney Int. 2019. 95(5):1091-1102. doi: 10.1016/j.kint.2018.11.023

B. Koautorschaften

  1. Bauer OB, Hachmöller O, Borovinskaya O, Sperling M, Schurek HJ, Ciarimboli G, Karst U. LA-ICP-TOF-MS for rapid, all-elemental and quantitative bioimaging, isotopic analysis and the investigation of plasma processes. J. Anal. At. Spectrom., 2019, 34, 694. doi: 10.1039/c8ja00288f.
  2. Becker F, Voß T, Mohr A, Mehdorn AS, Schütte-Nütgen K, Reuter S, Kabar I, Bormann E, Vowinkel T, Palmes D, Brockmann JG, Pascher A, Bahde R, Kebschull L, Vogel T. Impact of nighttime procedures on outcomes after liver transplantation. PLoS One. 2019;14(7):e0220124.
  3. Harder JL, Menon R, Otto EA, Zhou J, Eddy S, Wys NL, O'Connor C, Luo J, Nair V, Cebrian C, Spence JR, Bitzer M, Troyanskaya OG, Hodgin JB, Wiggins RC, Freedman BS, Kretzler M; European Renal cDNA Bank (ERCB); Nephrotic Syndrome Study Network (NEPTUNE). Organoid single cell profiling identifies a transcriptional signature of glomerular disease. JCI Insight. 2019;4(1). pii: 122697. doi: 10.1172/jci.insight.122697
  4. Kwok E, Rodriguez DJ, Kremerskothen J, Nyarko A Intrinsic disorder and amino acid specificity modulate binding of the WW2 domain in kidney and brain protein (KIBRA) to synaptopodin. J Biol Chem. 2019. pii: jbc.RA119.009589. doi: 10.1074/jbc.RA119.009589.
  5. Moschall R, Rass M, Rossbach O, Lehmann G, Kullmann L, Eichner N, Strauss D, Meister G, Schneuwly S, Krahn MP, Medenbach J. Drosophila Sister-of-Sex-lethal reinforces a male-specific gene expression pattern by controlling Sex-lethal alternative splicing. Nucleic Acids Res. 2019;47(5):2276-2288. doi: 10.1093/nar/gky1284
  6. Papp R, Nagaraj C, Zabini D, Nagy BM, Lengyel M, Skofic Maurer D, Sharma N, Egemnazarov B, Kovacs G, Kwapiszewska G, Marsh LM, Hrzenjak A, Höfler G, Didiasova M, Wygrecka M, Sievers LK, Szucs P, Enyedi P, Ghanim B, Klepetko W, Olschewski H, Olschewski A. Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension. Eur Respir J. 2019; 5;53(6). pii: 1800965. doi: 10.1183/13993003.00965-2018.
  7. Rolfes L, Pfeuffer S, Ruck T, Melzer N, Pawlitzki M, Heming M, Brand M, Wiendl H, Meuth SG. Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic Review. J Clin Med. 2019;8(10). pii: E1623. doi: 10.3390/jcm8101623
  8. Rong X, Han Q, Lin X, Kremerskothen J, Wang E. FRMPD1 activates the Hippo pathway via interaction with WWC3 to suppress the proliferation and invasiveness of lung cancer cells. Cancer Manag Res. 2019 Apr 18;11:3395-3410. doi: 10.2147/CMAR.S194512. eCollection 2019
  9. Schmitz B, Kleber ME, Lenders M, Delgado GE, Engelbertz C, Huang J, Pavenstädt H, Breithardt G, Brand SM, März W, Brand E. Genome-wide association study suggests impact of chromosome 10 rs139401390 on kidney function in patients with coronary artery disease. Sci Rep. 2019 Feb 26;9(1):2750.
  10. Schmitz B, Niehues H, Lenders M, Thorwesten L, Klose A, Krüger M, Brand E, Brand SM. Effects of High-Intensity Interval Training on Microvascular Glycocalyx and Associated microRNAs. Am J Physiol Heart Circ Physiol. 2019;316(6):H1538-H1551
  11. Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B; Athena Study Group. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int. 2019;96(1):231-244. doi: 10.1016/j.kint.2019.01.041.
  12. Späth MR, Bartram MP, Palacio-Escat N, Hoyer KJR, Debes C, Demir F, Schroeter CB, Mandel AM, Grundmann F, Ciarimboli G, Beyer A, Kizhakkedathu JN, Brodesser S, Göbel H, Becker JU, Benzing T, Schermer B, Höhne M, Burst V, Saez-Rodriguez J, Huesgen PF, Müller RU, Rinschen MM. The proteome microenvironment determines the protective effect of preconditioning in cisplatin-induced acute kidney injury. Kidney Int. 2019;95(2):333-349. doi: 10.1016/j.kint.2018.08.037.
  13. Xiao K, Lu D, Hoepfner J, Santer L, Gupta S, Pfanne A, Thum S, Lenders M, Brand E, Nordbeck P, Thum T. Circulating microRNAs in Fabry Disease. Sci Rep. 2019;9(1):15277.

A. Erst- oder/und Letztautorschaften

  1. Bonse J, Wennmann DO, Kremerskothen J, Weide T, Michgehl U, Pavenstädt H, Vollenbröker B. Nuclear YAP localization as a key regulator of podocyte function. Cell Death Dis. 2018;9(9):850. doi: 10.1038/s41419-018-0878-1.
  2. Braun DA, Lovric S, Schapiro D, Schneider R, Marquez J, Asif M, Hussain MS, Daga A, Widmeier E, Rao J, Ashraf S, Tan W, Lusk CP, Kolb A, Jobst-Schwan T, Schmidt JM, Hoogstraten CA, Eddy K, Kitzler TM, Shril S, Moawia A, Schrage K, Khayyat AIA, Lawson JA, Gee HY, Warejko JK, Hermle T, Majmundar AJ, Hugo H, Budde B, Motameny S, Altmüller J, Noegel AA, Fathy HM, Gale DP, Waseem SS, Khan A, Kerecuk L, Hashmi S, Mohebbi N, Ettenger R, Serdaroğlu E, Alhasan KA, Hashem M, Goncalves S, Ariceta G, Ubetagoyena M, Antonin W, Baig SM, Alkuraya FS, Shen Q, Xu H, Antignac C, Lifton RP, Mane S, Nürnberg P, Khokha MK, Hildebrandt F. Mutations in multiple components of the nuclear pore complex cause nephrotic syndrome. J Clin Invest. 2018;128(10):4313-4328. doi: 10.1172/JCI98688.
  3. Gromnitza S, Lepa C, Weide T, Schwab A, Pavenstädt H, George B. Tropomyosin-related kinase C (TrkC) enhances podocyte migration by ERK-mediated WAVE2 activation. FASEB J. 2018;32(3):1665-1676. doi: 10.1096/fj.201700703R.
  4. Hermann A*, Wennmann DO*, Gromnitza S, Edeling M, Van Marck V, Sudol M, Schaefer L, Duning K, Weide T, Pavenstädt H*, Kremerskothen J*. WWC proteins regulate hepatic cell differentiation and tumorigenesis via the Hippo signaling pathway. Hepatology. 2018; 67:1546-1559. doi: 10.1002/hep.29647. 2017
  5. Hochapfel F, Denk L, Maaßen C, Zaytseva Y, Rachel R, Witzgall R and Krahn MP. Electron microscopy of Drosophila garland cell nephrocytes: optimal preparation, immunostaining and STEM tomography. J Cell Biochem. 2018;119:8011–8021. doi: 10.1002/jcb.26702. [Epub ahead of print].
  6. Hornig J, Weinhage T, Schmidt LH, Buerke B, Schneider U,Pavenstädt H, Becker H, Gabriëls G. [Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment]. Z Rheumatol. 2018;77(10):952-957. doi: 10.1007/s00393-018-0565-8
  7. Hucke A, Park GY, Bauer OB, Beyer G, Köppen C, Zeeh D, Wehe CA, Sperling M, Schröter R, Kantauskaitè M, Hagos Y, Karst U, Lippard SJ, Ciarimboli G. Interaction of the New Monofunctional Anticancer Agent Phenanthriplatin With Transporters for Organic Cations. Front Chem. 2018 May 25;6:180. doi: 10.3389/fchem.2018.00180.
  8. Kuempers, P; Lukasz, A. The curse of angiopoietin-2 in ARDS: on stranger TI(E)des. Crit Care. 2018;22(1): 44
  9. Kullmann L and Krahn MP. Controlling the master: Upstream regulation of the tumour suppressor LKB1. Oncogene, 2018; 37: 3045–3057, doi: 10.1038/s41388-018-0145-z.
  10. Kullmann L and Krahn MP. Oligomerization and lipid binding of Par3 function redundantly to promote protein stability and epithelial polarization. Cell Mol Life Sciences, 2018; 75(17), 3269-3282.
  11. Lenders M, Brand E. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.J Am Soc Nephrol. 2018;29(9):2265-2278. doi: 10.1681/ASN.2018030329
  12. Lenders M, Neußer LP, Rudnicki M, Nordbeck P, Canaan-Kühl S, Nowak A, Cybulla M, Schmitz B, Lukas J, Wanner C, Brand SM, Brand E.Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease. J Am Soc Nephrol. 2018;29(12):2879-2889. doi: 10.1681/ASN.2018070740
  13. Lenders M, Schmitz B, Brand SM, Brand E. Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact? Orphanet J Rare Dis. 2018;13(1):171. doi: 10.1186/s13023-018-0916-1.
  14. Lenders M, Schmitz B, Brand SM, Föll D, Brand E. Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion. The Journal of Allergy and Clinical Immunology, 2018; 141(6):2289-2292.e7. doi: 10.1016/j.jaci.2017.12.1001.
  15. Lukasz AH,Kümpers P. [Angiopoietin-2 regulates endothelial glycocalyx]. Med Klin Intensivmed Notfmed. 2018;113(6):497-500. doi: 10.1007/s00063-018-0469-z.
  16. Michgehl U, Skryabin BV, Bayraktar S, Vollenbröker B, Ciarimboli G, Heitplatz B, Van Marck V, Gröne HJ, Pavenstädt H, Weide T. Nephron specific knockin of the PIKfyve binding deficient Vac14L156R mutant results in albuminuria and mesangial expansion. Am J Physiol Renal Physiol. 2018. 315(5):F1307-F1319. doi: 10.1152/ajprenal.00191.2018.
  17. Reuter S,Backhaus P,Becker H. Tendon swelling after kidney transplantation. Dtsch Arztebl Int. 2018 Sep 3;115(35-36):595. doi: 10.3238/arztebl.2018.0595.
  18. Rovas A; Lukasz A-H; Vink H, Urban M, Sackarnd J, Pavenstädt H; Kümpers P. Bedside analysis of the sublingual microvascular glycocalyx in the emergency room and intensive care unit - the GlycoNurse study. Scand J Trauma Resusc Emerg Med. 2018;26(1): 16
  19. Schelleckes K; Schmitz B; Lenders M; Mewes M; Brand SM; Brand E: ZFP226 is a novel artificial transcription factor for selective activation of tumor suppressor KIBRA. Scientific Reports 2018; 8: 4230, DOI: 10.1038/s41598-018-22600-6
  20. Schenk LK, Buchholz B, Henke SF, Michgehl U, Daniel C, Amann K, Kunzelmann K, Pavenstädt HJ. Nephron-specific knockout of TMEM16A leads to reduced number of glomeruli and albuminuria.Am J Physiol Renal Physiol. 2018. 315: F1777–F1786doi: 10.1152/ajprenal.00638.2017.
  21. Schenk LK, Ousingsawat J, Skryabin BV, Schreiber R, Pavenstädt H, Kunzelmann K. Regulation and Function of TMEM16F in Renal Podocytes. Int J Mol Sci. 2018;19(6). pii: E1798. doi: 10.3390/ijms19061798.
  22. Schenk LK, Pavenstädt H, Kümpers P. Fever and Pulmo-Renal Syndrome with Cholecystitis in a Traveller – a Differential Diagnostic Challenge. Dtsch med Wochenschr 2018; 143(04): 263-266
  23. Schütte-Nütgen K, Edeling M, Mendl G, Krahn MP, Edemir B, Weide T, Kremerskothen J, Michgehl U, Pavenstädt H. Getting a Notch closer to renal dysfunction: activated Notch suppresses expression of the adaptor protein Disabled-2 in tubular epithelial cells. FASEB J. 2019;33(1):821-832. doi: 10.1096/fj.201800392RR
  24. Schütte-Nütgen K, Tholking G, Suwelack B,Reuter S. Tacrolimus - Pharmacokinetic Considerations For Clinicians. Curr Drug Metab. 201;. 19(4):342-350 doi: 10.2174/1389200219666180101104159.
  25. Suwelack B, Wörmann V, Berger K, Gerß J, Wolters H, Vitinius F, Burgmer M and for the German SoLKiD consortium. Investigation of the physical and psychosocial outcomes after living kidney donation - a multicenter cohort study (SoLKiD - Safety of Living Kidney Donors). BMC Nephrology BMC series – open, inclusive and trusted. 2018; 19(1):83.doi: 10.1186/s12882-018-0871-z.
  26. Winterberg V, Cnyrim CD, Reuter S. Severe Delirium after Combined Pancreas and Kidney Transplantation. Dtsch Arztebl Int. 2018 Jul 9;115(27-28):476. doi: 10.3238/arztebl.2018.0476.

B. Koautorschaften

  1. Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, Schmidt LH, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C. An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia. Leukemia. 2018; 32(2):510-519. doi: 10.1038/leu.2017.208. 2017
  2. Bauer OB, Köppen C, Sperling M, Schurek HJ, Ciarimboli G, Karst U. Quantitative Bioimaging of Platinum via Online Isotope Dilution-Laser Ablation-Inductively Coupled Plasma Mass Spectrometry. Anal Chem. 2018;90(11):7033-7039. doi: 10.1021/acs.analchem.8b01429
  3. Becker F, Vogel T, Voß T, Mehdorn AS,Schütte-Nütgen K, Reuter S, Mohr A, Kabar I, Bormann E, Vowinkel T, Palmes D, Senninger N, Bahde R, Kebschull L. The weekend effect in liver transplantation. PLoS One. 2018;13(5):e0198035. doi: 10.1371/journal.pone.0198035
  4. Eisenberger U, Budde K, Lehner F, Sommerer C, Reinke P, Witzke O, Wüthrich RP, Stahl R, Heller K, Suwelack B, Mühlfeld A, Hauser IA, Nadalin S, Porstner M, Arns W; ZEUS Study Investigators. Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. BMC Nephrol. 2018;19(1):154. doi: 10.1186/s12882-018-0950-1.
  5. Germain DP, Brand E, Cecchi F, Kempf J, Laney DA, Linhart A, Maródi L, Nicholls K, Pieruzzi F, Shankar SP, Waldek S, Wanner C, Jovanovic A. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female Fabry patients: a multicenter Fabry Registry study. Mol Genet Genomic Med. 2018;6:492–503doi: 10.1002/mgg3.389
  6. Guttmann S, Bernick F, Naorniakowska M, Michgehl U, Groba SR, Socha P, Zibert A, Schmidt HH. Functional Characterization of Novel ATP7B Variants for Diagnosis of Wilson Disease. Front Pediatr. 2018;6:106. doi: 10.3389/fped.2018.00106
  7. Guttmann S, Chandhok G, Reinartz Groba S, Niemietz C, Sauer V, Gomes A, Ciarimboli G, Karst U, Zibert A, Schmidt HH. Organic cation transporter 3 mediates cisplatin and copper cross-resistance in hepatoma cells. Oncotarget 2017;9(1):743-754. doi: 10.18632/oncotarget.23142.
  8. Han Q, Kremerskothen J, Lin X, Zhang X, Rong X, Zhang D, Wang E.WWC3 inhibits epithelial-mesenchymal transition of lung cancer by activating Hippo-YAP signaling. Onco Targets Ther. 2018;11:2581-2591. doi: 10.2147/OTT.S162387.
  9. Hoffmann F, Kraft A, Heigl F, Mauch E, Koehler J, Harms L, Kümpfel T, Köhler W, Ehrlich S, Bayas A, Weinmann-Menke J, Beuker C, Henn KH, Ayzenberg I, Ellrichmann G, Hellwig K, Klingel R, Fassbender CM, Fritz H, Slowinski T, Weihprecht H, Brand M, Stiegler T, Galle J, Schimrigk S. Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. Ther Adv Neurol Disord. 2018;11:1756286418774973. doi: 10.1177/1756286418774973.
  10. Höhne M, Frese CK, Grahammer F, Dafinger C, Ciarimboli G, Butt L, Binz J, Hackl MJ, Rahmatollahi M, Kann M, Schneider S, Altintas MM, Schermer B, Reinheckel T, Göbel H, Reiser J, Huber TB, Kramann R, Seeger-Nukpezah T, Liebau MC, Beck BB, Benzing T, Beyer A, Rinschen MM: Single nephron proteomes connect morphology and function in proteinuric kidney disease. Kidney Int. 2018;93(6):1308-1319. doi: 10.1016/j.kint.2017.12.012.
  11. Kaufeld J, Weber LT, Kurschat C, Canaan-Kuehl S, Brand E, Oh J, Pape L. [Cystinosis: Diagnosis, cystine-depleting therapy, and transition]. Internist (Berl). 2018 Aug;59(8):861-867. doi: 10.1007/s00108-018-0416-3.
  12. Krämer J, Lenders M, Canaan-Kühl S, Nordbeck P, Üçeyler N, Blaschke D, Duning T, Reiermann S, Stypmann J, Brand SM, Gottschling T, Störk S, Wanner C, Sommer C, Brand E, Weidemann F. Fabry disease under enzyme replacement therapy – new insights in efficacy of different dosages. Nephrol Dial Transplant. 2018;33(8):1362-1372. doi: 10.1093/ndt/gfx319 IF(2017)=4,602
  13. Lehner LJ, Reinke P, Hörstrup J, Rath T, Suwelack B, Krämer BK, Budde K, Banas B. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: a multicenter, non-interventional study. Clin Transplant. 2018;32:e13142. doi: 10.1111/ctr.13142. 2017
  14. Lin W, Buscher K, Wang B, Fan Z, Song N, Li P, Yue Y, Li B, Li C, Bi H. Soluble CD83 Alleviates Experimental Autoimmune Uveitis by Inhibiting Filamentous Actin-Dependent Calcium Release in Dendritic Cells. Front Immunol. 2018;9:1567. doi: 10.3389/fimmu.2018.01567.
  15. Masthoff M, Helfen A, Claussen J, Roll W, Karlas A, Becker H, Gabriëls G, Riess J, Heindel W, Schäfers M, Ntziachristos V, Eisenblätter M, Gerth U, Wildgruber M. Multispectral optoacoustic tomography of systemic sclerosis. J Biophotonics. 2018;11(11):e201800155. doi: 10.1002/jbio.201800155.
  16. Parry BA, Chang AM, Schellong SM, House SL, Fermann GJ, Deadmon EK, Giordano NJ, Chang Y, Cohen J, Robak N, Singer AJ, Mulrow M, Reibling ET, Francis S, Griffin SM, Prochaska JH, Davis B, McNelis P, Delgado J, Kümpers P, Werner N, Gentile NT, Zeserson E, Wild PS, Limkakeng AT Jr, Walters EL, LoVecchio F, Theodoro D, Hollander JE, Kabrhel C. International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs. Thromb Res. 2018 Jun;166:63-70. doi: 10.1016/j.thromres.2018.04.003.
  17. Posner MG, Upadhyay A, Ishima R, Kalli AC, Harris G, Kremerskothen J, Sansom MSP, Crennell SJ, Bagby S. Distinctive phosphoinositide- and Ca2+-binding properties of normal and cognitive performance-linked variant forms of KIBRA C2 domain. J Biol Chem. 2018;293(24):9335-9344. doi: 10.1074/jbc.RA118.002279.
  18. Pürkhauer K, Weymouth AJ, Pfeffer K, Kullmann L, Mulvihill E, Krahn MP, Müller DJ and Giessibl F. Imaging in Biologically-Relevant Environments with AFM Using Stiff qPlus Sensors. Scientific Reports;2018; 8(1):9330. doi: 10.1038/s41598-018-27608-6.
  19. Rauen T, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. J Am Soc Nephrol. 2018, 29 (1) 317-325. pii: ASN.2017060713. doi: 10.1681/ASN.2017060713. 2017
  20. Renschler FA, Bruekner SR, Salomon PL, Mukherjee A, Kullmann L, Schütz-Stoffregen MC, Henzler C, Pawson T, Krahn MP, Wiesner S.Structural basis for the interaction between the cell polarity proteins Par3 and Par6. Sci Signal. 2018;11(517). pii: eaam9899. doi: 10.1126/scisignal.aam9899.
  21. Schmidt N; Dressel A; Grammer TB; Gouni-Berthold I; Julius U; Kassner U; Klose G; Konig C; Koenig W; Otte B; Parhofer KG; Reinhard W; Schatz U; Schunkert H; Steinhagen-Thiessen E; Vogt A; Laufs U; Marz W. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry. Atherosclerosis 2018;277: 314-322.
  22. Sommerer C, Witzke O, Lehner F, Arns W, Reinke P, Eisenberger U, Vogt B, Heller K, Jacobi J, Guba M, Stahl R, Hauser IA, Kliem V, Wüthrich RP, Mühlfeld A, Suwelack B, Duerr M, Paulus EM, Zeier M, Porstner M, Budde K; ZEUS and HERAKLES study investigators. Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. BMC Nephrol. 2018;19(1):237. doi: 10.1186/s12882-018-1031-1.
  23. Thomas C, Zühlsdorf A, Hörtnagel K, Mulahasanovic L, Grauer OM, Kümpers P, Wiendl H, Meuth SG. A Novel PKD1 Mutation Associated With Autosomal Dominant Kidney Disease and Cerebral Cavernous Malformation. Front Neurol. 2018; 9: 383. doi: 10.3389/fneur.2018.00383

A. Erst- oder/und Letztautorschaften

  1. Bokemeyer A, Dziewas R, Wiendl H, Schwindt W, Bicsán P, Kümpers P, Pavenstädt H. Hyponatremia upon presentation to the emergency department - the need for urgent neuroimaging studies. Sci Rep. 2017;7(1):1953. doi: 10.1038/s41598-017-02030-6
  2. Dogliotti G, Kullmann L, Dhumale P, Thiele C, Panichkina O, Mendl G, Houben R, Haferkamp S, Püschel AW, Krahn MP. Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression. Nat Commun. 2017;8:15747.
  3. Engelbertz C, Reinecke H, Breithardt G, Schmieder RE, Fobker M, Fischer D, Schmitz B, Pinnschmidt HO, Wegscheider K, Pavenstädt H, Brand E. Two-year outcome and risk factors for mortality in patients with coronary artery disease and renal failure: The prospective, observational CAD-REF Registry. Int J Cardiol. 2017;243:65-72. doi: 10.1016/j.ijcard.2017.05.022
  4. Gerth HU, Pohlen M, Pavenstädt H, Schmidt H. [Extracorporeal liver support of liver failure]. Z Gastroenterol. 2017 Apr;55(4):383-393. doi: 10.1055/s-0043-100020
  5. Gerth HU, Pohlen M, Thölking G, Pavenstädt H, Brand M, Hüsing-Kabar A, Wilms C, Maschmeier M, Kabar I, Torner J, Pavesi M, Arroyo V, Banares R, Schmidt HHJ. Molecular Adsorbent Recirculating System Can Reduce Short-Term Mortality Among Patients With Acute-on-Chronic Liver Failure-A Retrospective Analysis Crit Care Med. 2017; 45(10):1616-1624. doi: 10.1097/CCM.0000000000002562
  6. Gerth HU, Pohlen M, Thölking G, Pavenstädt H, Brand M, Wilms C, Hüsing-Kabar A, Görlich D, Kabar I, Schmidt HH. Molecular adsorbent recirculating system (MARS) in acute liver injury and graft dysfunction: Results from a case-control study. PLoS One. 2017;12(4):e0175529. doi: 10.1371/journal.pone.0175529
  7. Golle L,Gerth HU, Beul K, Heitplatz B, Barth P, Fobker M, Pavenstädt H, Di Marco GS, Brand M. Bone marrow-derived cells and their conditioned medium induce microvascular repair in uremic rats by stimulation of endogenous repair mechanisms. Sci Rep. 2017;7(1):9444. doi: 10.1038/s41598-017-09883-x.
  8. Granado D, Müller D, Krausel V, Kruzel-Davila E, Schuberth C, Eschborn M, Wedlich-Söldner R, Skorecki K, Pavenstädt H, Michgehl U, Weide T. Intracellular APOL1 Risk Variants Cause Cytotoxicity Accompanied by Energy Depletion. J Am Soc Nephrol. 2017; 28 (11) 3227-3238. pii: ASN.2016111220. doi: 10.1681/ASN.2016111220
  9. Harrach S, Edemir B, Schmidt-Lauber C, Pap T, Bertrand J, Ciarimboli G. Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts. Sci Rep. 2017;7(1):1258. doi: 10.1038/s41598-017-01438-4
  10. Hochapfel F, Denk L, Mendl G, Schulze U, Maaßen C, Zaytseva Y, Pavenstädt H, Weide T, Rachel R, Witzgall R, Krahn MP. Distinct functions of Crumbs regulating slit diaphragms and endocytosis in Drosophila nephrocytes. Cell Mol Life Sci. 2017; 74(24):4573-4586. doi: 10.1007/s00018-017-2593-y.
  11. Kentrup D, Bovenkamp P, Busch A, Schuette-Nuetgen K, Pawelski H, Pavenstädt H, Schlatter E, Herrmann KH, Reichenbach JR, Löffler B, Heitplatz B, Van Marck V, Yadav NN, Liu G, van Zijl PCM, Reuter S, Hoerr V. GlucoCEST magnetic resonance imaging in vivo may be diagnostic of acute renal allograft rejection. Kidney Int. 2017;92(3):757-764. doi: 10.1016/j.kint.2017.04.015
  12. Lanvers-Kaminsky C, Ciarimboli G. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin. Pharmacogenomics. 2017;18(18):1683-1695. doi: 10.2217/pgs-2017-0125.
  13. Lanvers-Kaminsky, C; Zehnhoff-Dinnesen, AGA; Parfitt, R; Ciarimboli, G: Drug-induced Ototoxicity: Mechanisms, Pharmacogenetics, and Protective Strategies. Clinical Pharmacology & Therapeutics, 101 (4):491-500; 10.1002/cpt.603
  14. Lenders M, Schmitz B, Stypmann J, Duning T, Brand SM, Kurschat C, Brand E. Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease. Nephrol Dial Transplant. 2017; 32(12):2090-2097. doi: 10.1093/ndt/gfw334
  15. Lenders, M; Oder, D; Nowak, A; Canaan-Kuhl, S; Arash-Kaps, L; Drechsler, C; Schmitz, B; Nordbeck, P; Hennermann, JB; Kampmann, C; Reuter, S; Brand, SM; Wanner, C; Brand, E. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. Journal of Internal Medicine, 282 (3):241-253; 10.1111/joim.12647
  16. Lukasz A, Hillgruber C, Oberleithner H, Kusche-Vihrog K, Pavenstädt H, Rovas A, Hesse B, Goerge T, Kümpers P. Endothelial glycocalyx breakdown is mediated by angiopoietin-2. Cardiovasc Res. 2017;113(6):671-680. doi: 10.1093/cvr/cvx023
  17. Mewes, M; Nedele, J; Schelleckes, K;Bondareva, O; Lenders, M; Kusche-Vihrog, K; Schnittler, HJ; Brand, SM; Schmitz, B; Brand, E. Salt-induced Na+/K+-ATPase-alpha/beta expression involves soluble adenylyl cyclase in endothelial cells. Pflügers Archiv-European Journal of Physiology, 2017;469 (10):1401-1412
  18. Michgehl U, Pavenstädt H, Vollenbröker B. Cross talk between the Crumbs complex and Hippo signaling in renal epithelial cells. Pflugers Arch. 2017;469(7-8):917-926. doi: 10.1007/s00424-017-2004-0
  19. Morr M, Lukasz A, Rübig E, Pavenstädt H, Kümpers P. Sepsis recognition in the emergency department - impact on quality of care and outcome? BMC Emerg Med. 2017;17(1):11. doi: 10.1186/s12873-017-0122-9
  20. Schelleckes, K; Schmitz, B; Ciarimboli, G; Lenders, M; Pavenstadt, HJ; Herrmann, E; Brand, SM; Brand, E. Promoter methylation inhibits expression of tumor suppressor KIBRA in human clear cell renal cell carcinoma. Clinical Epigenetics, 9:109. doi 10.1186/s13148-017-0415-6
  21. Schenk LK, Möller-Kerutt A, Klosowski R, Wolters D, Schaffner-Reckinger E, Weide T, Pavenstädt H, Vollenbröker B. Angiotensin II regulates phosphorylation of actin-associated proteins in human podocytes. FASEB J. 2017; ;31(11):5019-5035. pii: fj.201700142R. doi: 10.1096/fj.201700142R
  22. Schulze U, Vollenbröker B,Kühnl A, Granado D, Bayraktar S, Rescher U, Pavenstädt H, Weide T. Cellular vacuolization caused by overexpression of the PIKfyve-binding deficient Vac14L156R is rescued by starvation and inhibition of vacuolar-ATPase. Biochim Biophys Acta Mol Cell Res. 2017;1864(5):749-759. doi: 10.1016/j.bbamcr.2017.02.012
  23. Schulze, U; Brast, S; Grabner, A; Albiker, C; Snieder, B; Holle, S; Schlatter, E; Schroter, R; Pavenstadt, H; Herrmann, E; Lambert, C; Spoden, GA; Florin, L; Saftig, P; Ciarimboli, G: Tetraspanin CD63 controls basolateral sorting of organic cation transporter 2 in renal proximal tubules. FASEB J., 31 (4):1421-1433; 10.1096/fj.201600901R APR 2017
  24. Schütte-Nütgen K, Boenisch O, Harrach H, Casey A, Guleria I, Najafian N, Sayegh MH, Gerard CJ, Subramaniam M. Divergent Function of Programmed Death-Ligand 1 in Donor Tissue versus Recipient Immune System in a Murine Model of Bronchiolitis Obliterans. Am J Pathol. 187(6):1368-1379. doi: 10.1016/j.ajpath.2017.02.007. 2017
  25. Schütte-Nütgen K, Thölking G, Dahmen M, Becker F, Kebschull L, Schmidt R, Pavenstädt H, Suwelack B, Reuter S. Is there a "weekend effect" in kidney transplantation? PLoS One. 2017;12(12):e0190227. Impact(2017)=2.766 FSP 0
  26. Thölking G, Gerth HU, Schuette-Nuetgen K, Reuter S.Influence of tacrolimus metabolism rate on renal function after solid organ transplantation. World J Transplant 2017, 7(1):26-33.
  27. Thölking G, Schuette-Nuetgen K, Vogl T, Dobrindt U, Kahl BC, Brand M, Pavenstädt H, Suwelack B, Koch R, Reuter S. Male kidney allograft recipients at risk for urinary tract infection? PLoS One. 12(11):e0188262. doi: 10.1371. 2017
  28. Weide T, Vollenbröker B, Schulze U, Djuric I, Edeling M, Bonse J, Hochapfel F, Panichkina O, Wennmann DO, George B, Kim S, Daniel C, Seggewiß J, Amann K, Kriz W, Krahn MP, Pavenstädt H. Pals1 Haploinsufficiency Results in Proteinuria and Cyst Formation. J Am Soc Nephrol. 2017;28(7):2093-2107. doi: 10.1681/ASN.2016040474

B. Koautorschaften

  1. Anuj, Arivazhagan L, Surabhi RP, Kanakarajan A, Sundaram S, Pitani RS, Mudduwa L, Kremerskothen J, Venkatraman G, Rayala SK. KIBRA attains oncogenic activity by repressing RASSF1A. Br J Cancer. 2017; 117, 553–562 doi: 10.1038/bjc.2017.192.
  2. Brettner F, Chappell D, Schwartz L, Lukasz A, Kümpers P, Becker BF, Reichart B, Rehm M, Bruegger D. Vascular Endothelial Dysfunction during Cardiac Surgery: On-Pump versus Off-Pump Coronary Surgery. Eur Surg Res. 2017;26;58(5-6):354-368.
  3. Cabrita I, Benedetto R, Fonseca A, Wanitchakool P, Sirianant L, Skryabin BV, Schenk LK, Pavenstädt H, Schreiber R, Kunzelmann K. Differential effects of anoctamins on intracellular calcium signals. FASEB J. 2017;31(5):2123-2134. doi: 10.1096/fj.201600797RR
  4. de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M; ELEVATE Study Group (Suwelack B). Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. Am J Transplant. 2017;17(7):1853-1867. doi: 10.1111/ajt.14186. Arthritis Res Ther.
  5. Grabner A, Schramm K, Silswal N, Hendrix M, Yanucil C, Czaya B, Singh S, Wolf M, Hermann S, Stypmann J, Di Marco GS, Brand M, Wacker MJ, Faul C: FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. Sci Rep. 2017;7(1): 1993
  6. Han Q, Lin X, Zhang X, Jiang G, Zhang Y, Miao Y, Rong X, Zheng X, Han Y, Han X, Wu J, Kremerskothen J, Wang E. WWC3 regulates the Wnt and Hippo pathways via Dishevelled proteins and large tumour suppressor 1, to suppress lung cancer invasion and metastasis. J Pathol. 2017;242(4):435-447. doi: 10.1002/path.4919.
  7. Hillen J, Geyer C, Heitzmann M, Beckmann D, Krause A, Winkler I, Pavenstädt H, Bremer C, Pap T, Korb-Pap A. Structural cartilage damage attracts circulating rheumatoid arthritis synovial fibroblasts into affected joints. Arthritis Res Ther. 2017;19(1):40. doi: 10.1186/s13075-017-1245-9.
  8. HPS3/TIMI55–REVEAL Collaborative Group  (…Otte B, Centofante L, Kremerskothen R,…) Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. 2017.
  9. Hu S, Leblanc AF, Gibson AA, Hong KW, Kim JY, Janke LJ, Li L, Vasilyeva A, Finkelstein DB, Sprowl JA, Sweet DH, Schlatter E, Ciarimboli G, Schellens J, Baker SD, Pabla N, Sparreboom A. Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity. Clin Transl Sci. 2017; 10, 412–420. doi: 10.1111/cts.12480
  10. Hüsing-Kabar A, Heinzow HS, Schmidt HH, Stenger C, Gerth HU, Pohlen M, Thölking G, Wilms C, Kabar I. Single-operator cholangioscopy for biliary complications in liver transplant recipients. World J Gastroenterol. 4;23(22):4064-4071. doi: 10.3748/wjg.v23.i22.4064. 2017
  11. Navarro D, San-Juan R, Manuel O, Giménez E, Fernández-Ruiz M, Hirsch HH,6, Grossi PA, Aguado JM; ESGICH CMV Survey Study Group, on behalf of the European Study Group of Infections in Compromised Hosts (ESGICH –Reuter S-) from the Society of Clinical Microbiology and Infectious Diseases (ESCMID). Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey. Transpl Infect Dis. 2017;19(6). doi: 10.1111/tid.12773.
  12. Nemcsik J, Cseprekál O, Egresits J, Kielstein J, Kümpers P, Lukasz A, Tabák Á, Marton A, Németh ZK, Járai Z, Godina G, Sallai L, Farkas K, Kiss I, Tislér A: The role of laser Doppler flowmetry tests, serum angiopoietin-2, asymmetric and symmetric dimethylarginine to predict outcome in chronic kidney disease. J Hypertens. 2017;35(5): 1109-1118
  13. Schmidt N, Grammer T, Gouni-Berthold I, Julius U, Kassner U, Klose G, König C, Laufs U, Otte B, Steinhagen-Thiessen E, Wanner C, März W. CaRe high - Cascade screening and registry for high cholesterol in Germany. Atheroscler Suppl. 2017;30:72-76. doi: 10.1016/j.atherosclerosissup.2017.05.015.
  14. Schmitz B, Schelleckes K, Nedele J, Thorwesten L, Klose A, Lenders M, Krüger M, Brand E, Brand SM Dose-Response of High-Intensity Training (HIT) on Atheroprotective miRNA-126 Levels. Front Physiol. 2017;8: 349
  15. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial  (…Otte B, Kremerskothen R….) Lancet 2017; 389: 2117–27
  16. Wahba R, Suwelack B, Arns W, Cakiroglu F, Eisenberger U, Feldkamp T, Hansen A, Ivens K, Klein T, Kribben A, Kurschat C, Lange U, Mühlfeld A, Nitschke M, Reuter S, Schulte K, Viebahn R, Woitas R, Hellmich M, Stippel DL. Rescue allocation and recipient oriented extended allocation in kidney transplantation-influence of the EUROTRANSPLANT allocation system on recipient selection and graft survival for initially nonaccepted organs. Transpl Int. 2017;30(12):1226-1233. doi: 10.1111/tri.12993.
  17. Zhang Y, Yan S, Chen J, Gan C, Chen D, Li Y, Wen J, Kremerskothen J, Chen S, Zhang J, Cao Y. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma. J Cell Mol Med. 2017;21(12): 3718–3729. doi: 10.1111/jcmm.13281.
  18. Ziemann M, Heßler N, König IR, Lachmann N, Dick A, Ditt V, Budde K, Reinke P, Eisenberger U, Suwelack B, Klein T, Westhoff TH, Arns W, Ivens K, Habicht A, Renders L, Stippel D, Bös D, Sommer F, Görg S, Nitschke M, Feldkamp T, Heinemann FM, Kelsch R: Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation. Nephrol Dial Transplant. 2017;32(5): 880-889

A. Erst- oder/und Letztautorschaften

  1. Buscher K, Wang H, Zhang X, Striewski P, Wirth B, Saggu G, Lütke-Enking S, Mayadas TN, Ley K, Sorokin L, Song J. Protection from septic peritonitis by rapid neutrophil recruitment through omental high endothelial venules. Nat Commun. 2016;7:10828. doi: 10.1038/ncomms10828
  2. Ciarimboli G: In reference to Immunohistochemical localization of OCT2 in the cochlea of various species. Laryngoscope. 2016;126(6):E231. doi: 10.1002/lary.25881
  3. Djuric I*, Siebrasse JP*, Schulze U*, Granado D, Schlüter MA, Kubitscheck U, Pavenstädt H*, Weide T*.: The C-terminal domain controls the mobility of Crumbs 3 isoforms. Biochim Biophys Acta. 2016;1863(6 Pt A):1208-17. doi: 10.1016/j.bbamcr.2016.03.008.
  4. Edeling M, Ragi G, Huang S, Pavenstädt H, Susztak K. Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog. 2016;12(7):426-39. doi: 10.1038/nrneph.2016.54.
  5. Gerth HU* , Pohlen M*, Görlich D, Thölking G, Kropff M, Berdel WE, Pavenstädt H, Brand M, Kümpers P.: Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study. PLoS One. 2016;11(5):e0154993. doi: 10.1371/journal.pone.0154993.
  6. Grabner A* , Kentrup D*, Mühlmeister M, Pawelski H, Biermann C, Bettinger T, Pavenstädt H, Schlatter E, Tiemann K, Reuter S: Noninvasive Imaging of Acute Renal Allograft Rejection by Ultrasound Detection of Microbubbles Targeted to T-lymphocytes in Rats. Ultraschall Med. 2016;37(1):82-91. doi: 10.1055/s-0034-1385796
  7. Grabner A*, Kentrup D*, Pawelski H, Mühlmeister M, Biermann C, Heitplatz B, Van Marck V, Bettinger T, Pavenstädt H, Schlatter E, Stypmann J, Tiemann K, Reuter S: Renal Contrast-Enhanced Sonography Findings in a Model of Acute Cellular Allograft Rejection. Am J Transplant. 2016;16(5):1612-9. doi: 10.1111/ajt.13648.
  8. Harrach S*, Schmidt-Lauber C*, Pap T, Pavenstädt H, Schlatter E, Schmidt E, Berdel WE, Schulze U, Edemir B, Jeromin S, Haferlach T, Ciarimboli G*, Bertrand J*. MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients. Blood Cancer J. 2016; 6:e470. doi: 10.1038/bcj.2016.79.
  9. Hucke A, Ciarimboli G. The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations. J Clin Pharmacol. 2016;56 Suppl 7:S157-72. doi: 10.1002/jcph.706
  10. Lenders M, Canaan-Kühl S, Krämer J, Duning T, Reiermann S, Sommer C, Stypmann J, Blaschke D, Üçeyler N, Hense HW, Brand SM, Wanner C, Weidemann F, Brand E: Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up. J Am Soc Nephrol. 2016;27(3):952-62. doi: 10.1681/ASN.2015030337
  11. Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühl S, Sommer C, Üçeyler N, Kampmann C, Karabul N, Giese AK, Duning T, Stypmann J, Krämer J, Weidemann F, Brand SM, Wanner C, Brand E: Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis. 2016;11(1):88. doi: 10.1186/s13023-016-0473-4
  12. Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E: Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease. J Am Soc Nephrol. 2016;27(1):256-64. doi: 10.1681/ASN.2014121226.
  13. Lenders M, Weidemann F, Kurschat C, Canaan-Kühl S, Duning T, Stypmann J, Schmitz B, Reiermann S, Krämer J, Blaschke D, Wanner C, Brand SM, Brand E: Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant. Orphanet J Rare Dis. 2016;11(1):54. doi: 10.1186/s13023-016-0441-z
  14. Reinecke H , Breithardt G, Engelbertz C, Schmieder RE, Fobker M, Pinnschmidt HO, Schmitz B, Bruland P, Wegscheider K, Pavenstädt H, Brand E: Baseline Characteristics and Prescription Patterns of Standard Drugs in Patients with Angiographically Determined Coronary Artery Disease and Renal Failure (CAD-REF Registry). PLoS One. 2016;11(2):e0148057. doi: 10.1371/journal.pone.0148057
  15. Reuter S*, Reiermann S*, Malyar V, Schütte-Nütgen K, Schmidt R, Pavenstädt H, Reinecke H, Suwelack B. A Comparison of Different Algorithms for the Assessment of Cardiovascular Risk in Patients at Waiting List for Kidney Transplantation. PLoS One. 2016;11(10):e0161927. doi: 10.1371/journal.pone.0161927
  16. Reuter S. Aktuelle Studie zur verzögerten Transplantatfunktion und akuter Rejektion. Nephrologe. 2016; 11:219–221
  17. Riese SB*, Buscher K*, Enders S, Kuehne C, Tauber R, Dernedde J. Structural requirements of mono- and multivalent L-selectin blocking aptamers for enhanced receptor inhibition in vitro and in vivo. Nanomedicine. 2016; 12(4):901-908. pii: S1549-9634(16)00003-4. doi: 10.1016/j.nano.2015.12.379.
  18. Rübig E, Stypmann J, Van Slyke P, Dumont DJ, Spieker T, Buscher K, Reuter S, Goerge T, Pavenstädt H, Kümpers P: The Synthetic Tie2 Agonist Peptide Vasculotide Protects Renal Vascular Barrier Function In Experimental Acute Kidney Injury. Sci Rep. 2016;6:22111. doi: 10.1038/srep22111
  19. Schenk LK, Schulze U, Henke S, Weide T, Pavenstädt H: TMEM16F Regulates Baseline Phosphatidylserine Exposure and Cell Viability in Human Embryonic Kidney Cells. Cell Physiol Biochem. 2016;38(6):2452-63. doi: 10.1159/000445596
  20. Schulze Blasum B, Schröter R, Neugebauer U, Hofschröer V, Pavenstädt H, Ciarimboli G, Schlatter E, Edemir B. The kidney-specific expression of genes can be modulated by the extracellular osmolality. FASEB J. 2016; 30(10):3588-3597.pii: fj.201600319R.
  21. Thölking G, Schmidt C, Koch R, Schuette-Nuetgen K, Pabst D, Wolters H, Kabar I, Hüsing A, Pavenstädt H, Reuter S, Suwelack B:  Influence of tacrolimus metabolism rate on BKV infection after kidney transplantation. Sci Rep. 2016;6:32273. doi: 10.1038/srep32273.
  22. Thölking G, Schuette-Nuetgen K, Kentrup D, Pawelski H, Reuter S. Imaging-based diagnosis of acute renal allograft rejection. World J Transplant. 2016;6(1):174-82. doi: 10.5500/wjt.v6.i1.174.
  23. Thölking G, Siats L, Fortmann C, Koch R, Hüsing A, Cicinnati VR, Gerth HU, Wolters HH, Anthoni C, Pavenstädt H, Suwelack B, Schmidt HH, Kabar I.: Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation. Ann Transplant 2016;21:167-79
  24. Willeke P, Schlüter B, Limani A, Becker H, Schotte H: Liver involvement in ANCA-associated vasculitis. Clin Rheumatol. 2016;35(2):387-94. doi: 10.1007/s10067-015-2882-5

B. Koautorschaften

  1. Breuckmann F, Remberg F, Böse D, Lichtenberg M, Kümpers P, Pavenstädt H, Waltenberger J, Fischer D.: Guideline-conforming timing of invasive management in troponin-positive or high-risk ACS without persistent ST-segment elevation in German chest pain units : Urban university maximum care vs. rural regional primary care. Herz. 2016;41(2):151-8. doi: 10.1007/s00059-015-4354-8
  2. Brinkmann BF, Steinbacher T, Hartmann C, Kummer D, Pajonczyk D, Mirzapourshafiyi F, Nakayama M, Weide T, Gerke V, Ebnet K: VE-cadherin interacts with cell polarity protein Pals1 to regulate vascular lumen formation. Mol Biol Cell. 2016; 27:2811-2821 pii: mbc.E16-02-0127
  3. Brückner M, Lenz P, Mücke MM, Gohar F, Willeke P, Domagk D, Bettenworth D: Diagnostic imaging advances in murine models of colitis. World J Gastroenterol. 2016;22(3):996-1007. doi: 10.3748/wjg.v22.i3.996.
  4. Dogan Onugoren M, Golombeck KS, Bien C, Abu-Tair M, Brand M, Bulla-Hellwig M, Lohmann H, Münstermann D, Pavenstädt H, Thölking G, Valentin R, Wiendl H, Melzer N, Bien CG. Immunoadsorption therapy in autoimmune encephalitides. Neurol Neuroimmunol Neuroinflamm. 2016 Feb 26;3(2):e207. doi: 10.1212/NXI.0000000000000207
  5. Engelbertz C, Brand E, Fobker M, Fischer D, Pavenstädt H, Reinecke H: Elevated copeptin is a prognostic factor for mortality even in patients with renal dysfunction. Int J Cardiol. 2016;221:327-332. doi: 10.1016/j.ijcard.2016.07.058.
  6. Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR, Brand E, Breithardt G, Bucklar-Suchankova G, Camm AJ, Cartlidge D, Casadei B, Chua WW, Crijns HJ, Deeks J, Hatem S, Hidden-Lucet F, Kääb S, Maniadakis N, Martin S, Mont L, Reinecke H, Sinner MF, Schotten U, Southwood T, Stoll M, Vardas P, Wakili R, West A, Ziegler A, Kirchhof P.: Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nat Rev Cardiol. 2016(4):230-7. doi: 10.1038/nrcardio.2015.194
  7. Fischer D, Remberg F, Böse D, Lichtenberg M, Kümpers P, Lebiedz P, Pavenstädt HJ, Waltenberger J, Breuckmann F.: How rapid is rapid? Exemplary results of real-life rapid rule-out troponin timing in troponin-positive acute coronary syndromes without persistent ST-segment elevation in two contrasting German chest pain unit facilities. Eur J Med Res. 2016;21:11. doi: 10.1186/s40001-016-0206-0
  8. Heitz FD, Farinelli M, Mohanna S, Kahn M, Duning K, Frey MC, Pavenstädt H, Mansuy IM: The memory gene KIBRA is a bidirectional regulator of synaptic and structural plasticity in the adult brain. Neurobiol Learn Mem. 2016;135:100-114. pii: S1074-7427(16)30128-9. doi: 10.1016/j.nlm.2016.07.028
  9. Hessner F, Dlugos CP, Chehab T, Schaefer C, Homey B, Gerke V, Weide T, Pavenstädt H*, Rescher U*: CC chemokine receptor 10 cell surface presentation in melanocytes is regulated by the novel interaction partner S100A10. Sci Rep. 2016;6:22649. doi: 10.1038/srep22649
  10. Klionsky DJ et al (Weide T, Pavenstädt H). Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1-222. doi: 10.1080/15548627.2015.1100356.
  11. Lidove, O; Barbey, F; Niu, DM; Brand, E; Nicholls, K; Bizjajeva, S; Hughes, DA. Fabry in the older patient: Clinical consequences and possibilities for treatment. Molecular Genetics and Metabolism, 2016; 118 (4):319-325; 10.1016/j.ymgme.2016.05.009
  12. Mavuluri J, Beesetti S, Surabhi R, Kremerskothen J, Venkatraman G, Rayala SK: Phosphorylation-Dependent Regulation of the DNA Damage Response of Adaptor Protein KIBRA in Cancer Cells. Mol Cell Biol. 2016;36(9):1354-65. doi: 10.1128/MCB.01004-15
  13. Moser J, Heeringa P, Jongman RM, Zwiers PJ, Niemarkt AE, Yan R, de Graaf IA, Li R, Ravasz Regan E, Kümpers P, Aird WC, van Nieuw Amerongen GP, Zijlstra JG, Molema G, van Meurs M: Intracellular RIG-I Signaling Regulates TLR4-Independent Endothelial Inflammatory Responses to Endotoxin. J Immunol. 2016;196(11):4681-91. doi: 10.4049/jimmunol.1501819
  14. Pattaro C, ….. Brand E…. et al., Fox CS. Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nat Commun. 2016;7:10023. doi: 10.1038/ncomms10023.
  15. Pillukat MH, Schomacher T, Baier P, Gabriëls G, Pavenstädt H, Schmidt HH: Early initiation of MARS® dialysis in Amanita phalloides-induced acute liver injury prevents liver transplantation. Ann Hepatol. 2016;15(5):775-87. doi: 10.5604/16652681.1212613. IF 2015 = 1,811
  16. Rodrigues R, Artieda M, Tejedor D, Martınez A, Konstantinova P, Petry H, Meyer C, Corzo D, Sundgreen C, Klor HU, Gouni-Berthold I, Westphal S, Steinhagen-Thiessen E, Julius U, Winkler K, Stroes E, Vogt A, Hardt P, Prophet H, Otte B, Nordestgaard BG, Deeb SS, Brunzell JD: Pathogenic classification of LPL gene variants reported to be associated with LPL deficiency J Clin Lipidol. 2016;10(2):394-409. doi: 10.1016/j.jacl.2015.12.015
  17. Rossaint J, Oehmichen J, Van Aken H, Reuter S, Pavenstädt HJ, Meersch M, Unruh M, Zarbock A: FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest. 2016;126(3):962-74. doi: 10.1172/JCI83470.
  18. Schmitz B, Thorwesten L, Lenders M, Duning T, Stypmann J, Brand E, Brand SM. Physical Exercise in Patients with Fabry Disease - a Pilot Study. Int J Sports Med. 2016 Dec;37(13):1066-1072
  19. Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler. 2016;22(8):1048-60. doi: 10.1177/1352458515607651.
  20. Siebrasse JP, Djuric I, Schulze U, Schlüter MA, Pavenstädt H, Weide T, Kubitscheck U. Trajectories and single-particle tracking data of intracellular vesicles loaded with either SNAP-Crb3A or SNAP-Crb3B. Data Brief. 2016;7:1665-9. doi: 10.1016/j.dib.2016.04.058.
  21. Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, Czaja MJ, Bartz R, Abraham R, Di Marco GS, Brand M, Wolf M, Faul C: Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016; 90(5):985-996. pii: S0085-2538(16)30236-8. doi: 10.1016/j.kint.2016.05.019
  22. Sommerer C , Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Wolters HH, Suwelack B, Klehr HU, Hauser IA, Stangl M, Nadalin S, Dürr M, Porstner M, May C, Wimmer P, Witzke O, Lehner F.: Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. Clin Nephrol. 2016;85(4):215-25. doi: 10.5414/CN108726
  23. Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Nashan B, Thaiss F.: Design and rationale of the ATHENA study - A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients. Trials. 2016;17:92. doi: 10.1186/s13063-016-1220-9
  24. Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N: A phosphotyrosine switch regulates organic cation transporters. Nat Commun. 2016;7:10880. doi: 10.1038/ncomms10880
  25. Wales P, Schuberth CE, Aufschnaiter R, Fels J, García-Aguilar I, Janning A, Dlugos CP, Schäfer-Herte M, Klingner C, Wälte M, Kuhlmann J, Menis E, Hockaday Kang L, Maier KC, Hou W, Russo A, Higgs HN, Pavenstädt H, Vogl T, Roth J, Qualmann B, Kessels MM, Martin DE, Mulder B, Wedlich-Söldner R. Calcium-mediated actin reset (CaAR) mediates acute cell adaptations. Elife. 2016 Dec 6;5. pii: e19850. doi: 10.7554/eLife.19850.
  26. Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, Boanta A, Gerß J, Meersch M: Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA. 2016;315(20):2190-9. doi: 10.1001/jama.2016.5828
  27. Zschiedrich S , Budde K, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hoerl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Lindner TH, Faerber L, Wimmer P, Stork R, Eckardt KU, Walz G: Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2016;31(2):284-9. doi: 10.1093/ndt/gfv077